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Human cytomegalovirus (HCMV) represents a massive burden on infected individuals 
and healthcare systems worldwide. Though HCMV is not normally disease causing in 
healthy individuals, it poses a significant threat to immunocompromised people and 
developing fetuses, causing a broad range of diseases due to its ability to infect several 
organ and tissue types. Current diagnostic and treatment modalities for HCMV are 
extremely limited in their scope. In the United States, HCMV testing is typically only 
done when one presents with possible HCMV-caused symptoms, as current methods are 
deemed unwarranted if no symptoms are presented in a patient. Additionally, if treatment 
is to be given, current antiviral drugs are limited to targeting only one aspect of HCMV’s 
replication cycle and, at times, can be rather toxic. As such, continued research and 
development is needed to create rapid, facile point–of-care diagnostics as well as identify 
new druggable targets to lessen the impact of infection. Utilizing a murine model system 
to study HCMV infection, we recently showed that precise detection of murine 
cytomegalovirus (MCMV) from the urine of infected mice was rapidly achieved through 
the use of a novel electrochemical immunoassay. By attaching glucose oxidase to an 
antibody recognizing MCMV, we readily detected MCMV at an electrode using 
chemistry similar to that used in modern day glucometers. Additionally, we characterized 
and identified a major role for a uniquely structured MCMV deubiquitinating enzyme 
(DUB) during infection. When the virus lacked DUB activity, levels of a virally encoded 
pro-inflammatory chemokine increased, leading to the mutant DUB virus’ dramatic 
attenuation in mice. As this enzyme is incredibly important for MCMV pathogenesis and 
 vii 
is highly conserved between MCMV and HCMV, it may serve as a viable target for 
antiviral therapies. Because HCMV infections persist for the lifetime of the individual, 
continued success in diagnosis and treatment of HCMV will be needed as long as humans 
exist as a species.  
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Chapter 1:  Introduction 
1.1 HUMAN CYTOMEGALOVIRUS: A GLOBAL BURDEN 
1.1.1 Human Cytomegalovirus Prevalence, Disease, and Treatment 
It seems unfathomable that despite years of tremendous scientific and 
technological advances, there remains a viral pathogen that infects 50-90% of the world’s 
population with no vaccine to effectively protect against it. This pathogen, human 
cytomegalovirus (HCMV) constitutes a significant health risk and massive financial 
burden to countries worldwide. HCMV causes an estimated $1.9 billion/year in the 
United States alone in medical costs [1], where greater than 50% of the nation’s 
population is infected with HCMV by the age of 40 [2]. Worldwide, HCMV 
seroprevalence tends to follow socioeconomic lines, with infection rates approaching 
100% in developing nations [3].  
HCMV belongs to the beta-herpesvirus sub-family of Herpesviridae. As such, it 
has an approximately 230kb linear dsDNA genome. Virions are organized as illustrated 
in Figure 1.1. Briefly, a capsid is surrounded by a cell-derived lipid bilayer envelope. 
Between the envelope and capsid lies the amorphous protein layer known as the tegument 
[4]. While generally not disease causing in immunocompetent hosts, HCMV poses a 
threat to developing fetuses, newborns, and immunocompromised adults. Though 
infection can occur at any point during a pregnancy, infections of developing fetuses 
occurring in the first trimester of pregnancy typically lead to more severe outcomes than 
those infected later. Newborns infected with HCMV prenatally are at risk for defects in 
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neural developmental, which can result in hearing loss, mental retardation, microcephaly, 
or combinations thereof [5]. At-risk adults include solid organ transplant recipients on 
anti-rejection medication, AIDs patients, and patients receiving chemotherapy [6]. These 
HCMV-infected individuals are at a greater risk of developing inflammatory conditions 
including retinitis [7], colitis, pneumotitis, or hepatitis [8]. Additionally, organ transplant 
recipients are at a greater risk of allograft loss due to HCMV infection [9].  Though 
vaccine development is ongoing, current vaccination efforts are in various stages of 
clinical trials [10] with nothing available to the public at this time. Modern treatment 
options for active HCMV infection utilize nucleoside analogs or HCMV DNA 
polymerase inhibitors including gangciclovir, valganciclovir, cidofovir, and foscarnet 
[11], which act by blocking DNA replication of the HCMV-encoded DNA polymerase. 
Perhaps not surprisingly, resistant populations of HCMV are continuously reported [12].  
Only recently have phase III clinical trials for a new class of anti-HCMV drugs shown 
real promise in attenuation of infection [13, 14]. Continued research into treatment and 
diagnosis is needed to effectively combat HCMV infection. In order to develop better 
diagnostic measures and understand the important viral contributions that allow HCMV 
to successfully replicate in a live host, relevant small animal model systems are essential. 
It is with these small animal model systems that we can begin understanding the efficacy 




Figure 1.1: Cartoon schematic of HCMV (or MCMV) virion organization. 
 
An icosahedral capsid, surrounding a linear dsDNA genome (~230kb), is surrounded by a 
lipid bilayer serving as an envelope, packaging the virion. Between the lipid envelope 
and capsid is an amorphous protein layer known as the tegument. The lipid bilayer is 






1.2 MODEL SYSTEMS FOR HCMV STUDY 
1.2.1 Murine Cytomegalovirus (MCMV) as a model beta-herpesvirus  
While studies of HCMV have yielded significant insight into the molecular 
mechanisms governing infection, these analyses are limited to cell culture. Unlike some  
in vivo infection systems developed to study other herpesviruses [15], the 
cytomegaloviruses are species specific, which prevents the use of HCMV in animal 
model systems [16]. In order to learn what contributions virally-encoded products make 
to infection in a live mammalian host, small animal model systems must be utilized. 
Though CMV infection models using rats and guinea pigs exist, pathogenesis etiology in 
these systems remains relatively understudied. Over the decades, CMV virologists have 
made heavy use of murine model systems. These model systems are incredibly valuable, 
especially with the advent of modern genetic techniques (CRISPR/Cas9) [17], in that 
mice are becoming more genetically tractable. This allows researchers to better 
understand the contributions of host proteins to CMV infection. 
Murine cytomegalovirus (MCMV), like HCMV, is a beta-herpesvirus with a 
large, linear dsDNA genome.  Additionally, MCMV shares significant similarity with 
HCMV in its virion structure (Figure 1.1). MCMV shares a significant amount of genetic 
and biological similarity with HCMV. While differences do exist between HCMV and 
MCMV, many of the MCMV core proteins share significant sequence and functional 
similarity [18]. These core proteins tend to localize to the middle of their respective 
genomes and are typically involved in entry, replication, and egress. Comparative 
analyses on the functions and roles of proteins conserved between HCMV and MCMV 
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have allowed researchers to define the roles of CMV proteins during infection of natural 
hosts. Though the MCMV model system has been instrumental in advancing our 
understandings of cytomegalovirus biology as a whole, there are limitations. MCMV 
does not serve as a good model for studying congenital infection as MCMV does not 
readily cross the placental barrier [19]. Additionally, route of infection and the immune 
status of the mouse influence the pathogenicity of MCMV [20]. Thus, when designing 
MCMV studies to most closely mimic HCMV infection, these limitations must be taken 
into consideration. So long as the proper precautions are taken in experimental design, 
significant and important insight can be gleaned using MCMV model systems, as 
illustrated in Chapter 3 of this dissertation.   
1.3 CURRENT HCMV DIAGNOSTIC MEASURES 
1.3.1 Current Screening Methods for HCMV 
 When one considers the prevalence of HCMV infection and the slew of diseases 
and developmental deformities it can cause, it is surprising that early screening for 
infection is not more common. Typically, individuals are only diagnosed when disease 
symptoms are present. In the case of an expecting mother, these symptoms include those 
resembling infectious mononucleosis with negative test results for Epstein-Barr virus or 
signs of hepatitis that test negative for hepatitis A, B, and C [21]. Since the greatest risk 
of complications to the developing infant occurs during the first trimester of pregnancy 
[5], testing early and often should be of great importance.  
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Presently used screening methods for HCMV infection involve IgG or IgM 
testing for exposure to the virus [22], PCR-based methods for the detection of HCMV 
genome present in patient blood, urine, or amniotic fluid samples, as well as culturing of 
possibly infected samples with permissible cells (See Table 2.1) [23]. Unfortunately, 
these diagnostic tests require significant sample preparation (i.e. serum isolation and 
DNA extraction) and importantly, are currently not implemented as point-of-care 
measures in the United States. Interestingly, only 9 countries (Israel, France, Belgium, 
Spain, Italy, Germany, Austria, Portugal, and the Netherlands) regularly screen pregnant 
women serologically for HCMV [24]. As these countries implement regular testing for 
HCMV seropositivity, cost may not prove as big of a cost barrier as previously thought. 
In fact, predictive models suggest that universal HCMV screening would be a cost-
effective strategy, assuming passive immunization could achieve at least a 47% reduction 
in clinical disease [25]. These data all point us in a direction toward universal testing. As 
such, implementing rapid, facile methods requiring little to no sample preparation for 
diagnosis would be of benefit or could be used in conjunction with current diagnostic 
measures. Direct detection of virus, as opposed to immunoglobulin directed against 
HCMV antigen, would be of high priority so as to indicate whether an infection is active 
at the time of testing. 
1.3.2 Using electrochemistry for the detection of interesting species 
Electrochemistry is a field of chemistry concerned with the interrelation of 
electrical and chemical effects [26]. Electrochemistry is a powerful tool and is highly 
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amenable to the study of a number of interesting biological problems [27]. Of particular 
interest is the use of electrochemical methods that have been implemented heavily in the 
development of various biosensors [28]. A number of different molecules can be detected 
using electrochemical means. Perhaps the most popular and well-known utilization of 
electrochemical biosensors is seen with glucometers for the measurement of blood 
glucose concentrations [29]. Certain cancer-associated biomarkers have been detected 
with great sensitivity, with detection limits reaching sub-femtomolar ranges in some 
cases [30, 31]. Additionally, electrochemical nanobiosensors have been incredibly useful 
for the detection of trace amounts of various metals, harmful organic compounds, 
biomolecules, as well as microorganisms contained in or sitting on various foods [32]. In 
fact, due to their relative ease of use, portability, and cost effectiveness, the development 
of electrochemical detectors for species of interest is an exciting and burgeoning field 
[28].  
1.3.3 Electrochemical Analysis Using Collision Electrochemistry 
Many of the measurements scientists make during their experiments are 
ultimately mean values derived from a multitude of experiments over ensemble amounts 
of species. While these results are meaningful, they lack the resolution that would allow 
one to characterize and identify the contributions of individual molecules or species to 
the calculated mean values. Single molecule analyses, on the other hand, allow the 
researcher to observe the functional heterogeneity inherent in a sample, precise 
localization of a molecule, and kinetic properties of molecule function [33, 34]. The 
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science of electrochemistry provides one with a powerful set of tools to query systems 
traditionally measured by ensemble methods [35]. These types of experiments led to a 
field of stochastic electrochemistry that was first reported in 2004 by Lemay and co-
workers analyzing the collision of latex beads on ultramicroelectrodes (UMEs) [36]. 
Since then, the field of electrochemical collisions has generated significant interest in the 
electrochemistry community as it allows for the discrete detection of singular particles or 
even molecules in solution [37]. In order to observe stochastic processes on UMEs, one 
must decrease the concentration such that the collision of analyte species with the UME 
surface is on the order of one every few seconds. Thus, inherent in these experiments are 
limits of quantitation at sub-picomolar levels. For example, the femtomolar detection of 
ions has also been reported [38, 39]. One collision technique most relevant to this 
dissertation and of interest due to its high reproducibility of results is termed blocking 
[40]. In these experiments, a reaction is driven at the electrode surface (such as the 
oxidation of ferrocene methanol to ferrocenium methanol). Particles that collide with an 
electrode and adhere irreversibly are said to “block” the flux of ferrocene methanol to the 
electrode surface, thereby decreasing the overall current (Figure 1.2a). This manifests as 
a sharp change (i.e. decrease) in current as measured by the now blocked electrode 
(Figure 1.2b). According to the “classic” or U.S. plotting convention for amperometry 
current vs. time (i-t) curves, oxidation events at the electrode are plotted in the 4
th
 
quadrant in a Cartesian coordinate plane. Therefore, changes in current toward 0 are 
decreases in current (Figure 1.2b). The movement, or mass transfer, of particles to the 
surface of the electrode can be explained in a stochastic sense by considering the 
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frequency, f, with which analyte species collide with the electrode, given by the following 
equation: 
f = 4DCaNA (Equation 1) 
where D is the diffusion coefficient, estimated using the Stokes-Einstein approximation 
[41], C is the concentration, a is the radius of the UME, and NA is Avagadro’s Number. 
Thus, by studying the frequency of particle collisions and the change in current each time 
there is a collision at the electrode, one can learn the size range and possibly even the 













Figure 1.2: Collision and the subsequent blocking of the flux of redox active molecules at 
an electrode surface. 
 
A) Without any obstruction, the oxidation of a mediator molecule (e.g. ferrocene 
methanol) can be carried out at an electrode surface. Upon collision and blocking of the 
electrode surface by some particle, the oxidation of the mediator molecule is blocked, 
therefor blocking the current. B) Individual blocking events are seen as stepwise 
decreases in current by measuring the amount of current passing through an electrode 











While this tool is incredibly powerful and simple compared to other single 
molecule analyses, it is non-specific [42]. This means that anything in solution can 
potentially collide with the electrode and cause a change in current. However, if one can 
specifically label a species of interest such that a specific current change (e.g. a current 
increase) occurred upon the species of interest colliding with an electrode, the collision 
method could be used to positively identify particles in solution at the sub-picomolar 
level (Figure 1.3). With a detection scheme such as this, one could imagine extending 
these ideas to the detection of a number of different pathogens, which, in this scheme, act 
as the colliding particles. Chapter 2 describes work in collaboration with the laboratory of 
Allen J. Bard (UT Austin) in which a method to specifically detect viral particles at the 
30 fM level was achieved. This method was then extended to the detection of virus in 
urine of infected mice [43].  
While a correct diagnosis is important in order to determine the appropriate 
treatment regimen for a patient, resolution of the infection is essential for a patient to 
make a full recovery. As such, new viral targets for inhibition need to be identified in 
order that novel, less toxic inhibitors are developed. As previously stated, current HCMV 
treatment regimens only target viral DNA replication. While this is a logical strategy as 
DNA replication is an essential process to produce viral progeny, resistance to these 
drugs is increasing. In order to better treat HCMV infections, new drug targets must be 
identified. As host ubiquitin systems are necessary for HCMV infection, possible targets 
for anti-HCMV therapies may include viral proteins that manipulate the ubiquitin system.   
In the following section, examples of the specific ways herpesviruses interact with the 
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ubiquitin system are presented, emphasizing the contributions of uniquely structured viral 
deubiquitinating enzymes and how they may be viable targets for pharmacological 














Figure 1.3: An electrochemical collision scheme demonstrating a current increase upon 
collision of a species of interest with an electrode. 
 
A) A redox active species, being oxidized at an electrode, can be replenished 
enzymatically through the reduction of the oxidized mediator molecule upon collision at 
an electrode surface of species capable of doing so. B) Upon discrete collision of the 
reducing particle, the resulting amperometry manifests as stepwise increases in current 













1.4 HERPESVIRUSES AND THE UBIQUITIN SYSTEM 
1.4.1 Ubiquitin: a post-translational modification with a diverse functional range 
Ubiquitin is a small ~8 kD protein that serves as a post translational modification 
(PTM) in cells. Its covalent attachment to target proteins depends on a cascade of E1 
activating, E2 conjugating, and E3 ligating enzymes. E1 activating enzymes are charged 
with ubiquitin on their active site cysteine in an ATP-dependent manner. The ubiquitin 
molecule is then transferred to the active site cysteine residue of an E2 conjugating 
enzyme. This E2 enzyme then interacts with a specific E3 enzyme, which facilitates the 
ligation of the ubiquitin molecule onto the target protein (Figure 1.4). Substrate 
specificity is defined by interactions of E3 ubiquitin ligating enzymes with their targets. 
In the human genome, there are about 2 E1 enzymes, about 40 E2 enzymes, and around 
600 E3 ligating enzymes [44]. With an estimate of around 20,000-25,000 genes in the 
human genome [45], these E3 ligating enzymes must possess the ability to recognize a 







Figure 1.4: The ubiquitin cascade. 
In an ATP-dependent manner, ubiquitin is attached to an E1 activating enzyme. Transfer 
of the ubiquitin molecule from an E1 to an E2 conjugating enzyme is performed. E2 
interaction with an E3 ligating enzyme facilitates the transfer of ubiquitin to a target 












Though only a single protein, the function-altering potential ubiquitin possesses is 
quite amazing. Ubiquitin molecules are attached via the C-terminal glycine to the ε-amine 
group on lysine residues via an isopeptide bond. From here, ubiquitin chains can be 
assembled any number of different ways. Ubiquitin contains 7 internal lysine residues 
(K6, K11, K27, K29, K33, K48, and K63) and an N-terminal methionine which can all 
serve as sites upon which to build ubiquitin chains [46].  
With the ability to be conjugated a number of ways, ubiquitin modifications can 
have significant functional heterogeneity. The most well studied ubiquitin linkages, K48 
and K63, serve to modify targets proteins for destruction by the 26S proteasome and 
serve as a signal for the modified protein to participate in signaling pathways, 
respectively [46]. The other linkages, so-called “non-canonical” linkages, have been 
shown to have diverse roles in cells. K6 linkages have been shown to be involved in 
mitophagy [47-50]. K11 linkages have been shown to be heavily preferentially produced 
during early G1 and mitosis stages of the cell cycle [51]. This linkage plays a role similar 
to K48, in that it promote proteasomal degradation in some cases [52] while serving a 
protective role in others [53]. K27 linkages have been observed on mitochondrial 
trafficking protein Miro1 which slows down its own degradation and acts as a signal for 
mitochondrial clearance [54]. Additonally, K27 ubiquitin linkages are involved in 
controlling innate immune responses [55]. K29 linkages have been shown to be involved 
in growth and development pathways as well as affecting mRNA stability [56]. K33 
linkages have been shown to be involved in post-golgi transport [57]. As clearly 
evidenced here, ubiquitin plays a diverse yet essential role in cells.  
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While ubiquitin can rapidly elicit effects on protein functionality, this must be 
balanced with the potential to reverse these processes when needed. To this end, 
deubiquitinating enzymes, or DUBs, catalyze the removal of ubiquitin linkages from 
proteins to effectively reverse the effects ubiquitin once had. In humans, several classes 
of DUBs exist. These DUBs function in a number of different cellular processes, ranging 
from cell cycle regulation to regulating proteasomal degradation to DNA repair [58]. 
Mammalian DUBs can be divided in to 5 different classes: the ubiquitin C-terminal 
hydrolases (UCH), the ubiquitin specific proteases (USP), the ovarian tumor (OTU) 
domain containing DUBs, the Josephin domain (MJD) containing DUBs, and the 
JAB1/MPN/Mov34 metalloenzyme (JAMM) domain containing DUBs. The first four are 
cysteine proteases while the last class cleaves ubiquitin via a metalloproteolytic 
mechanism [58]. As DUBs serve a number of different roles under normal conditions, 
ranging from control over protein levels to trafficking of proteins [59], their importance 
must not be undermined. In fact, as discussed in section 1.4.2 and in more detail in the 
remaining sections, herpesvirus manipulation of the ubiquitin system not only includes 
directing ubiquitin attachment, but catalyzing its release, suggesting herpesviruses usurp 
multiple aspects of the ubiquitin system.  
1.4.2 Herpesvirus manipulation of the ubiquitin system 
Since the processes of ubiquitin attachment and removal are critical to optimal 
cellular function [59], it comes as no surprise that many viruses have evolved 
mechanisms to hijack the ubiquitin system for their own means [60]. One could argue 
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that the most masterful manipulators of host ubiquitin systems belong the family 
Herpesviridae as these pathogens encode numerous proteins evolved to hijack ubiquitin 
pathways [61]. For example, herpes simplex type 1 virus (HSV-1) encodes an E3 ligating 
enzyme known as infected cell protein 0 (ICP0). ICP0 E3 ubiquitin ligating activity 
targets a number of different proteins involved in innate immune signaling, the DNA 
damage response, and intrinsic immune responses to facilitate replication [62].  Kaposi’s 
sarcoma associated herpesvirus (KSHV) and murine gammaherpesvirus 68 (MHV68) 
also encode E3 ubiquitin ligating enzymes. KSHV encodes two E3’s: K3 and K5. These 
two enzymes are responsible for facilitating the ubiquitination and subsequent 
degradation of many cell surface localized immunomodulatory proteins [63]. The 
MHV68 E3 enzyme, mK3 performs a similar function, facilitating the degradation of 
MHC class I presentation [64]. While their targets differ, these E3 ubiquitin ligating 
enzymes operate similarly in that they promote the dampening of the host immune 
responses to infection.  
Although the HCMV genome does not encode any known E3 ligating enzymes, it 
does encode proteins that facilitate the ubiquitination and subsequent degradation of 
MHC I and II (US2 and US11). These two HCMV genes are not E3 ubiquitin ligating 
enzymes themselves. However, both US2 and US11 hijack the cellular endoplasmic 
reticulum-associated degradation (ERAD) machinery to facilitate the degradation of the 
peptide presenting complex, MHC class I. That is to say, they facilitate the extraction, 
ubiquitination, and subsequent proteasomal degradation of MCH class I [65]. Like HSV-
1, KSHV, and MHV68, HCMV manipulation of the ubiquitination system modulates the 
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host response to infection. Though these examples only describe a few virally-encoded 
proteins that manipulate the ubiquitin system, they serve to illustrate that herpesviruses 
must utilize the host ubiquitin system in order to effectively navigate host responses to 
infection.  
As evidenced above, not all herpesviruses encode E3 ubiquitin ligating enzymes. 
Interestingly, all herpesviruses from the three sub-families (alpha, beta, and gamma) do 
encode deubiquitinating enzymes (DUBs). This DUB activity lies in N-terminus of a 
conserved herpesvirus gene known as the large tegument protein (LTP) [66]. The 
tegument constitutes the amorphous space between the viral capsid and lipid envelope 
and contains a number of proteins critical for viral entry, assembly, and egress [67]. As 
the name suggests, these viral proteins lie within the herpesvirus tegument in close 
contact with the capsid. Herpesvirus LTPs have been shown to be critical in several 
capacities during entry, assembly, and egress. For example, the HCMV LTP UL48 may 
aid in genome deposition into the nucleus in cooperation with another tegument protein, 
UL47, upon capsid interaction with the nuclear pore complex [68]. Recent work has also 
shown that the HSV-1 LTP, UL36, serves as a scaffold for the assembly of other 
tegument protein [69]. Additionally, impressive work from the Pellett laboratory has 
demonstrated that the HCMV LTP, UL48, is critical for assembly compartment 
formation [70]. 
Over the past decade, much work has been conducted on the herpesvirus DUBs. 
Structural analyses of the MCMV DUB, M48, revealed that although herpesvirus DUBs 
seem to belong to the papain superfamily of proteases, they are distinctly structured and 
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have unique interactions with ubiquitin [71]. Even though the structure of herpesvirus 
DUBs appears conserved, functional studies have identified a variety of targets (Table 
1.2). However, much of the work characterizing the roles of herpesvirus DUBs has been 
done on the alpha- and gamma-herepsviruses, with only limited work conducted with 
beta-herpesviruses, which will be outlined in the sections below.      
1.4.3 Alpha-herpesvirus DUBs: roles during infection 
Much of the initial work uncovering the functions of herpesvirus DUBs has 
focused on the roles that alpha-herpesvirus DUBs served during infection. The archetypal 
alpha-herpesvirus, HSV-1, is a significant cause of morbidity. Specifically, HSV-1 
primarily causes lesions in mucosal membranes [15]. The HSV-1 DUB protein UL36, 
was the first described over ten years ago [66]. Protein alignment analysis subsequently 
revealed that other members of Herpesviridae appeared to encode for similar enzymes. 
As these DUBs did not align with any known cellular DUBs at the time, a novel class of 
DUBs was established, termed the herpesvirus tegument ubiquitin specific proteases 
(htUSPs). Single- and multi-step replication kinetics with a UL36  mutant (C40A) 
revealed only a modest replication defect in cell culture [72]. Though not necessary for 
replication in vitro, initial studies characterizing the role of HSV-1 UL36 
deubiquitination activity during infection showed that UL36 acts on TRAF3. 
Deubiquitination of TRAF3 resulted in an inability of Tank-binding kinase 1 (TBK1) to 
bind to TRAF3 and propagate signaling. The activity of UL36 therefore ultimately results 
in a diminished type 1 interferon (IFN) response [72]. Recent work has also demonstrated 
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that HSV-1 UL36 blocks activation of NFκB following infection by deubiquitinating the 
NFκB antagonist, IkBa, thus preventing its degradation thereby preventing activation of 
the NFκB response [73].  
Pseudorabies virus (PRV), another alpha-herpesvirus, also encodes a DUB 
(UL36) in the N-terminus of its LTP.  As PRV can cause significant neurological disease 
in infected pigs [74], the pig industry is vested in treating and protecting livestock against 
infection. Similar to HSV-1, inactivation of the PRV DUB by mutagenesis of the 
catalytic cysteine (C26S) resulted in a modest decrease in replication in cell culture. 
Interestingly, mice infected with mutant DUB PRV survived twice as long as mice 
infected with a wildtype (WT) virus control. Additionally, mutant DUB PRV exhibited a 
delay in neuroinvasion not observed in mice infected with a WT virus [75]. These data 
indicate the PRV DUB activity is important for PRV pathogenesis. Work from Gregory 
Smith’s laboratory independently arrived at a similar conclusion. Their work 
demonstrated that the PRV DUB was essential for initial neuroinvasion, but not 
subsequent neuron-to-neuron infection [76]. In fact, through the use of a technique 
known as di-glycine proteomics, Huffmaster and co-workers determined that this 
neuroinvasion was dependent on the auto-deubiquitination of a specific lysine residue 
(K442) of UL36. This deubiquitination of UL36 allowed transmission to nerve terminals 
and subsequent neuroinvasion [77]. While not shown to be the “switch” allowing for 
successful neuroinvasion by HSV-1, the positionally conserved lysine residue in HSV-1 
UL36 (K636) was also found to be heavily ubiquitinated in HSV-1 mutant DUB infected 
cells. This conservation suggests a similar phenomenon is occurring in HSV-1.    
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Unlike other alpha-herpesviruses, Marek’s disease virus (MDV), an alpha-
herpesvirus associated with chickens, does not infect or go latent in neurons, but instead 
infects B- and T-cells. T-cells that are latently infected may transform, ultimately leading 
to T-cell lymphoma and death of the infected poultry [78]. Like other herpesviruses, 
MDV contains a DUB in the N-terminus of its LTP (UL36). While not necessary in cell 
culture, a lack of DUB activity led to a significant decrease in the incidence of 
lymphomas in infected chickens [79, 80]. Additionally, the researchers showed that DUB 
domain structure, not the catalytic cysteine, of UL36 was important for in vitro and in 
vivo replication [80].  
1.4.4 Gamma-herpesvirus DUBs: roles during infection 
Like the alpha-herpesviruses, the gamma-herpesviruses share the conserved DUB 
function in their respective LTPs [66]. Kaposi’s sarcoma associated herpesvirus (KSHV) 
is a gamma-herpesvirus and is the causative agent of Kaposi’s sarcoma, primary effusion 
lymphomas, and multicentric Castleman’s disease [81, 82]. Like other herpesvirus DUBs, 
the DUB of KSHV, ORF64, has the ability to cleave lysine 48 (K48) and lysine 63 (K63) 
linked ubiquitin molecules [82]. Though silencing of the entire gene leads to a decrease 
in replication, it is not clear what the contribution is of ORF64 DUB activity to KSHV 
infection. Interestingly, in transfected cells, ORF64 appears to antagonize host antiviral 
responses similar to UL36 in HSV-1. Specifically, KSHV ORF64 and the murine 
gammaherpesvirus 68 (MHV68) DUB (also called ORF64) were able to deubiquitinate 
the RNA sensor, retinoic acid-inducible gene I (RIG-I), which prevents the induction of 
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type I IFN. Additionally, both KSHV and MHV68 replicated to higher levels in cells 
lacking RIG-I, indicating that RIG-I restricts their replication [83]. These studies, 
however, did not address whether the DUB of either KSHV or MHV68 had a direct effect 
on RIG-I during an infection. 
      In vivo analyses characterizing the role of gamma-herpesvirus DUBs 
conducted utilizing MHV68 have begun addressing the role of the gamma-herpesvirus 
DUB in small animals (Mus musculus). Like other gamma-herpesviruses, MHV68 enters 
latency in B-cells [84]. This small animal model system serves as a valuable system to 
determine the contribution of conserved gamma-herpesvirus genes to infection. Initial 
experiments revealed that MHV68 encodes a functional DUB [85]. Later studies 
examining the contributions of the MHV68 DUB to infection revealed that the DUB 
activity was not necessary for replication in cell culture, similar to other studies on 
herpesvirus DUB mutants. Interestingly, researchers discovered that a DUB mutant virus 
was rapidly cleared from the spleens of infected mice but was able to enter latency as 
well as the WT control [86]. This conclusion remains somewhat controversial, as a more 
recent study revealed that a mutant DUB MHV68 did not enter latency efficiently. This 
switch to latency was found to be dependent on the stimulator of interferon genes or 
STING protein [87].  
Perhaps the most well characterized herpesvirus DUB is that of Epstein-Barr virus 
(EBV), BPLF1. EBV is a gamma-herpesvirus that infects over 95% of people worldwide. 
Normally asymptomatic, approximately 200,000 cases of cancer each year can be 
attributed to EBV infection [88]. Over the years BPLF1 has been attributed a number of 
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different functions. Initial studies revealed that in addition to possessing DUB activity 
[89], the DUB domain of BPLF1 (aa 1-246) interacts with the virally encoded 
ribonucleotide reductase large subunit (RR1). Deubiquitination of RR1 by BPLF1 
reduces the ribonucleotide reductase activity in EBV, suggesting the DUB has a role in 
controlling replication [90].  
BPLF1 is also unique from other herpesvirus DUBs in that it has the unique 
ability to deneddylate, proteins modified by NEDD8 [91]. NEDD8 is a ubiquitin-like 
protein responsible for post translational modification of the Cullin family of proteins, 
which serve as scaffolds for the assembly of multicomponent RING E3 ligases (CRLs) 
[92]. As Cullin proteins serve as major targets of neddylation and BPLF1 can act as a 
deneddylase, it was reasoned that BPLF1 might be targeting Cullins proteins. In fact, 
BPLF1 was shown to bind Cullins to regulate CRL activity, which led to the 
accumulation of CDT1, a critical protein that licenses DNA for replication [93], and 
subsequent deregulation of the cell cycle, and increased viral DNA synthesis [91]. In 
addition to promoting viral DNA synthesis, BPLF1 can promote the accumulation of host 
chromosomal lesions through the deubiquitination of PCNA and subsequent de-
regulation of DNA lesion repair. This may be one mechanism by which EBV promotes 
the transformation of B-cells [94]. In addition to these functions in manipulating DNA 
replication and repair, BPLF1 has been shown to antagonize innate immune signaling. 
BPLF1 has been shown to deubiquitinate TRAF6, thereby inhibiting NFkB activation and 
subsequent antiviral responses [95, 96].      
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1.4.5 Beta-herpesvirus DUBs: roles During Infection 
Systematic, functional analyses defining beta-herpesvirus DUB contributions to 
infection represent the minority of herpesvirus DUB studies. Although the only 
herpesvirus DUB structure currently known is that of the beta-herpesvirus MCMV DUB 
M48, targets of this DUB still elude researchers. However, studies of CMV DUBs have 
shown not only that the DUB is functional, but that it is active during infection. Early 
work from Schlieker and colleagues showed that the N-terminus of M48 possessed DUB 
activity and that this DUB activity is dependent on a catalytic triad of consisting of 
cysteine (C23), aspartic acid (D156), and histidine (H158) [89]. Additionally, this new 
class of DUB, termed the herpesvirus tegument ubiquitin specific proteases (htUSPs), 
contains a unique β-hairpin critical for ubiquitin and ubiquitin-like (Ubl) protein 
distinction [71].  
More recent work by Kim and co-workers showed that the HCMV DUB, UL48, 
was expressed and active during infection. Like other herpesvirus DUBs, activity was not 
required for replication in cell culture. In fact, the contribution of UL48’s DUB activity 
was only realized in multi-step growth analyses [97]. The UL48 DUB domain also 
contributes stability to viral particles, aiding in infectivity, and actively targets itself for 
deubiquitination leading to its stabilization [98]. Although these two studies from Jin-
Hyun Ahn’s laboratory identified several roles for CMV DUBs during infection, until 
recently, it was not known what contributions beta-herpesvirus DUBs made to infection 
in a natural host.  
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Uncovering the roles that herpesvirus DUBs assume during infection presents 
itself as an incredibly important set of tasks. As these DUBs are uniquely structured, they 
have the potential to serve as druggable targets. Continued research into the basic biology 
governing unique viral enzymatic contributions to infection is crucial to identify targets 
and develop pharmacological therapies.  In Chapter 3, I will describe my work which 
identified a primary role for the M48 DUB during infection of mice. From our results and 
the significant structural similarity between the MCMV DUB and the HCMV DUB, we 
believe that the DUB of HCMV is a potential target for future pharmacological 
intervention.  












Table 1.1: Alpha-, beta-, and gamma-herpesvirus DUBs and their functions. 
 
This table summarizes numerous functions that have been attributed to herpesvirus DUBs 
over the past 10-15 years. As evidenced by the amount of text, much of the work 









Chapter 2: Specific, sensitive detection of murine cytomegalovirus using 
electrochemical methods1   
2.1 INTRODUCTION 
Electrochemistry is a branch of chemistry that is concerned with the interrelation 
of electrical and chemical effects [26]. It is an exciting field of study that has proven 
incredibly useful for the development of a variety of valuable sensor technologies. These 
sensors can and have been developed to detect a number of different relevant biological 
markers as well as possible food contaminants [32]. In the case of biomarker detection, 
sensitive detection of a number of different biological markers can be useful as a point-
of-care-diagnostic measure for a variety of different diseases such as cancer [99, 100] and 
various infectious diseases [101, 102].   
                                                 
1 Large portions of this chapter have been previously published. Author contributions are described in the 
publications. Briefly, A.T.H. performed research, analyzed data, and helped to write the papers. J.E.D. and 
A.T.H. contributions were equal in publication 2 listed below.  
1. Dick JE, Hilterbrand AT, BoikaA, Upton JW, Bard AJ. 2015. Electrochemical detection of a 
single cytomegalovirus at an ultramicroelectrode and its antibody anchoring. PNAS 112(17): 
5303-5308. 
2. Dick JE*, Hilterbrand AT*, Strawsine LM, Upton JW, Bard AJ. 2016. Enzymatically 
enhanced collisions on ultramicroelectrodes for specific and rapid detection of individual viruses. 





One particular popular focus of electrochemistry is the study of distinct collisions 
at ultramicroelectrodes (UMEs). With diameters on the order of micrometers to 
nanometers, these tiny electrodes offer researchers the unique opportunity to observe 
small current events not detectable with larger electrodes. Collision electrochemistry has 
been applied to the study of a number of different hard nanoparticles, particularly 
particles made of various metals, metal oxides, and organic materials [36, 103-113]. 
While a number of techniques have been developed to observe and measure the results 
from collisions at an electrode, the most robust and reproducible method is one known as 
“blocking” [40] (Figure 1.3). In a blocking event, a particle in solution will encounter an 
electrode, irreversibly adhere to it, and subsequently block any flux of redox active 
species at the electrode [40]. The resulting blocking event can be observed as a current 
step using amperometry, or measurements of current flux. This blocking event results in a 
sharp decrease in current, which leads to a new current steady state until the next 
blocking even occurs. 
Recent experiments utilizing collision electrochemistry methods have included 
the analysis of biologically relevant molecules of interest, like DNA and proteins [37, 
114]. In fact, using collision electrochemistry, one can analyze singular collision events 
and learn about single molecule properties from these phenomena [37]. Due to the 
inherent sensitivity of this technique [38, 39], its application to pathogen detection is an 
intriguing possibility. However, no collision methodologies have been investigated for 
the detection of relevant pathogens, such as viruses. As described in Chapter 1, one of the 
 30 
most prevalent viral pathogens worldwide is human cytomegalovirus (HCMV). As such, 
HCMV detection is a priority so that infected individuals might be treated. 
Cytomegaloviruses (CMVs) are the prototypic members of the beta-herpesvirus 
family. These large (~200 nm diameter) dsDNA viruses establish lifelong latent 
infections after primary infection and do not cause significant disease in healthy 
individuals. However, immunocompromised individuals infected with human 
cytomegalovirus (HCMV) are at a significantly greater risk of morbidity and mortality 
[115], including patients receiving chemotherapeutics, AIDS patients, and organ 
transplant recipients. Moreover, HCMV congenital infection is a leading cause of birth 
defects and developmental disabilities including hearing and vision loss, microcephaly, 
and cognitive disabilities [116]. Thus, highly sensitive and rapid detection of CMV 
infection in patients is an important part of mitigating transmission and disease. Like 
most herpesviruses, HCMV is highly species specific. Therefore, valuable small animal 
model systems exist to study CMV / host relationships. Murine cytomegalovirus 
(MCMV) serves as an important model system for HCMV pathogenesis, sharing 
significant genetic and biological characteristics with HCMV. MCMV provides a 
powerful, genetically tractable infection system in a natural mouse host and has yielded 
significant insights into CMV biology [20].  
One particularly saddening reality regarding HCMV infection is that diagnosis 
and confirmation is typically only done when patients present with possible HCMV-
caused symptoms. As HCMV has a significant potential to cause terrible disease, it is 
rather interesting that it is only regularly screened for in expecting mothers in 9 countries 
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worldwide, not including the United States [24]. HCMV is also not regularly screened for 
in immunocompromised individuals. When detection of HCMV is required, relatively 
time consuming techniques, with varying degrees of sensitivity, exist for the detection of 
CMV, including ELISA methods, sensitive PCR techniques, culturing, and microscopy 
(Table 2.1). While fairly reliable, these methods require significant sample preparation 
and can take anywhere from hours to days to perform. 
As such, rapid, sensitive tools are critically important for initial diagnoses and for 
the continued monitoring of individuals infected with HCMV. While the collision method 
of blocking allows for this sought after level of sensitivity (theoretical detection limit of 1 
virus particle) and rapid detection, it is inherently non-specific [43]. In a sample 
containing a complex mixture of particles of different makeup, it would be impossible to 
discern between different particles simply based on the resulting current change upon 
collision and subsequent blocking of an electrode. For that reason, if collision 
electrochemistry is to be used for pathogen detection, one needs a way to specifically 
identify differences between the varieties of particles likely to be in solution. 
Two methods developed for the specific detection of MCMV, in purified samples 
as well as from the urine of infected mice, are described in the following sections in 
Chapter 2. Both methodologies rely on the collision of particles with an electrode; 
however, they differ in the output read. In order to gain specificity in the detection 
schemes, both methods to be described rely on the use of a previously described 
neutralizing antibody against the MCMV glycoprotein, gB (Mab 97.3) [117]. In the first 
method, polystyrene beads, functionalized with an antibody that recognizes the FC 
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portion of Mab 97.3, interact with MCMV and Mab 97.3, ultimately resulting in a 
decrease in the frequency of blocking collisions and an increase in the amount of current 
blocked when collisions do occur. The second method relies on that same neutralizing 
antibody, which is now functionalized with a glucose oxidase enzyme (GOx). Using 
electrochemistry very similar to that used in modern day glucometers [29], we show that 
MCMV collision events can be detected as discrete stepwise increases in current at an 
electrode, in contrast to the previous method. This proves powerful in that it is 
distinguishable from possible background collisions. These two methods, those opposite 







Table 2.1: Comparison of several different HCMV detection techniques. 
 
Several diagnostic measures exist for the detection of HCMV by indirect or direct 
methods. Each method has advantages and disadvantages over the others. These methods 










2.2.1 Electrochemical detection of discrete MCMV collisions 
Prior to the specific detection of MCMV, the electrochemical response upon 
blocking of an electrode needed to be determined for MCMV. Approximately 5.2 x 10
5 
plaque forming units (PFUs) / ml (~0.86 pM) of virus were incubated with a 10 μm 
platinum UME in the presence of 500 mM potassium ferrocyanide (KFCN). This redox 
active species was chosen due to its incomplete dissolution [118-120]. If one were to use 
a redox active species which dissolves completely, agglomeration of colloidally 
suspended virions may occur, which would affect virion collision and detection. As seen 
in Figure 2.1b, discrete collision events caused by MCMV are observed at the electrode. 
As mentioned in Figure 1.3, when oxidation is blocked, by a virus for example, the 
observed blocking of anodic events is plotted as discrete current steps that are decreasing 
in value (going toward 0) (Figure 2.1b). By calculating the frequency of the collision 
events (# collisions / sec), one can obtain a diffusion coefficient (D) for a given particle, 
given by Eq. 1. From this diffusion coefficient, one can calculate the radius of a particle 






where rparticle is the radius of the particle, kB is Boltzman’s constant, T is temperature, and 
η is the viscosity of the continuous phase. Using these equations, the size of a particle can 
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be determined. These relationships were used in section 2.2.2 to discriminate between 













Figure 2.1: Electrochemical detection of MCMV by “blocking” in KFCN.  
 
A) Cartoon diagram illustrating the general organization of an MCMV virion. B) MCMV 
adsorption event onto an electrode surface showing the blocking of the oxidation of 
KFCN at the electrode surface. The panel to the right shows a typical blocking response 
due to MCMV collisions. In this experiment, MCMV is blocking 500mM KFCN at a 10 
μM Pt UME, where the applied voltage (Eappl) = +0.4 V vs. Ag/AgCl. 
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2.2.2 Electrochemical detection of discrete MCMV collisions with MCMV-specific 
antibody 
 
Like other herpesviruses, the MCMV capsid is surrounded by a lipid bilayer 
known as the envelope. Throughout the envelope are a number of different MCMV 
glycoproteins important for various phenomena, such as viral entry, assembly, and egress 
[182]. One essential viral glycoprotein is glycoprotein B, or gB. This protein is necessary 
for the fusogenic steps resulting in MCMV lipid bilayer fusion with the plasma 
membrane of a susceptible cell [121]. Antibodies directed against gB can prevent 
infection, or neutralize the virus’ ability to infect a cell [117]. As previously mentioned, 
blocking electrochemistry has the powerful capability to allow the researcher to discern 
particle size differences [37]. To showcase the ability of this electrochemical blocking 
technique to discern particle size differences, gB antibody (Mab 97.3), a kind gift from 
Dr. Michael Mach, was incubated with MCMV. The collision frequencies of MCMV-
anti-gB were compared to MCMV alone. Utilizing Nanoparticle Tracking Analysis 
(NTA) via a Nanosight instrument, one can measure particle movements in solution by 
illuminating the particles with light from a laser. After recording these movements, 
software is able to trace the movement of the particles. From this, a diffusion coefficient 
can be calculated. By using the Stokes-Einstein relationship (Equation 2), one can back 
calculate the hydrodynamic radius of a particle. As illustrated in Table 2.2, the 
hydrodynamic radii of MCMV and MCMV-gB were readily determined. Of significant 
interest is the resulting difference seen in the radii. The difference of 17 nm (MCMV-
gBRadius – MCMVRadius) agrees very well with the published length of IgG antibody, 
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which is approximately 14.5 nm [122]. Based on these measurements, it is very likely 
singular collision events are being recorded at the electrode. Additionally, it highlights 
the sensitivity of collision electrochemistry when using ultramicroelectrodes. While this 
blocking method has proved that MCMV and MCMV-Ab can be discriminated based on 
the calculated particle size, it still does not allow for specific detection of MCMV. If Mab 
97.3 were to be incubated with a biological sample thought to contain MCMV, there 
would likely be a number of blocking events similar to MCMV-Ab. In that case, there 
would be no way to discern whether MCMV was present or not. Therefore, we set out to 



























Values from nanoparticle tracking analysis. 
 
Table 2.2: Statistics of MCMV and MCMV-gB antibody, values of current step sizes, 






































2.2.3 Selectivity of MCMV detection by antibody anchoring of PSBs 
 
As stated previously, the collision method is non-specific, meaning that any 
particle in solution could possibly collide with the measuring electrode and subsequently 
cause a current step. Because of this, it is necessary to include some means of specifically 
detecting MCMV by collision electrochemistry. In order to do this, 750 nm polystyrene 
beads (PSBs) functionalized with an antibody capable of recognizing the FC portion of the 
gB antibody were mixed with MCMV and gB antibody. This experiment is illustrated in 
Figure 2.2a. In order to negate the potential background collisions that may occur as a 
result of unbound virus hitting the electrode, the redox active species (KFCN) was held at 
a concentration of 100 mM. By maintaining a dilute enough concentration of KFCN, 
unbound virus that blocks the electrode will not change current measurements at the 
electrode above that of the background. Therefore, holding KFCN at this concentration 
allows for the direct observation of PSBs and the effect the virus has on the beads without 
having to de-convolute the collisions of two different species. As shown in Figure 2.2b 
left panel, PSB collisions with the electrode cause observable current steps as measured 
by amperometry. However, when MCMV and gB antibody are added, the frequency of 
those collisions and height of the current steps changes dramatically. Due to the 
agglomeration of PSBs with MCMV and gB (Figure 2.5b-e), the frequency of collisions 
decreases dramatically as the larger aggregates do not diffuse as readily as before. 
Additionally, aggregates caused by the addition of virus and gB antibody block more of 
the UME, meaning individual current decreases are much greater than the average current 
changes measured with PSBs alone (Figure 2.2b, right graph).  
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Figure 2.2: Selectivity of MCMV detection by antibody anchoring of PSBs. 
A) Schematic representation of the collision experiments with PSBs radius, 750 nm, 
binding to the virus through the primary antibody (green Y). The secondary antibodies 
(maroon Ys) are specific to the Fc region of the primary antibody. B) Electrochemical 
current responses with and without virus. Without the virus, collisions of PSBs are 
observable with a characteristic frequency and current step height, ΔI. Upon addition of 
virus, the frequency drops, relative to the frequency of PSBs alone, and larger current 










To represent these observations in an averaged fashion over several blocking 
experiments, collision frequency percentages are plotted against binned current step 
ranges, measured in picoamperes (pA) (Figure 2.3a). When gB antibody and PSBs are 
mixed, observed current step ranges primarily fall between 101-150 pA. When PSBs and 
MCMV are mixed in a 1:1 ratio in the presence of gB antibody, a dramatic shift in the 
current step ranges is observed (201-250 pA). Additionally, an increase in the diversity of 
collision percentage frequencies is observed due to a greater distribution of current steps. 
It is hypothesized that this is due to higher order aggregates of MCMV, PSB, and 
antibody (Figure 2.5b-e). When murid gamma-herpesvirus 68 (MHV68) is mixed with 
the PSBs and gB antibody, a similar current step range as compared to PSBs and gB 
antibody was observed (101-150 pA), suggesting that the shift in current step ranges is 
dependent on MCMV.  
To show that the gB antibody was specific to MCMV and not MHV68, we 
performed a neutralization assay and measured the resulting infectivity by plaque assay. 
Briefly, increasingly dilute concentrations of gB antibody were incubated with MCMV or 
MHV68. As expected, MCMV was sufficiently neutralized at high antibody 
concentrations and this effect decreased as the antibody concentration decreased. When 
the same neutralization assay was performed with MHV68, the infectivity of MHV68 
was virtually unaffected (Figure 2.3b). These results tell us that the antibody is specific to 
MCMV, as it is incapable of neutralizing MHV68, likely because it is not able to 





Figure 2.3: PSB aggregation is dependent on the MCMV-antibody interaction. 
 
A) Current step distributions of the amount of collisions counted (collision fraction) as a 
function of current step binning. PSBs and virus are in a 1:1 mol ratio. Current step size 
distributions were determined for PSB and MAb 97.3 (blue trace), PSB and MAb 97.3 
with MCMV (red trace), and PSB and MAb 97.3 with MHV68 (green trace). Aggregates 
of n = 1, 2, 3 and higher order were counted using amperometry of 100 mM KFCN 
dissolved in the aqueous continuous phase on a 10-μm Pt UME. The potential was held at 
+0.4 V vs. Ag/AgCl. (B and C) Plaque reduction neutralization tests for MCMV and 






























In addition to an increase in current step size upon the mixing of PSBs, gB 
antibody, and MCMV, a decrease in collision frequency at the electrode was also 
observed. These observations are plotted in Figure 2.4. When MCMV-gB antibody 
conjugate was mixed with PSBs at a 15:1 ratio (i.e. excess virus), collision frequencies 
decreased over 80% when compared to PSBs alone. This decrease in collision frequency 
is likely due to the larger aggregates formed when MCMV, antibody, and PSBs are 
combined (Figure 2.5b-e) as larger objects do not diffuse as readily as smaller objects. By 
tracking the changes in collision frequency and current step height, we demonstrated that 
a qualitative diagnosis for MCMV’s presence can be made. While this method 
demonstrates that MCMV can be specifically detected using collision electrochemistry, 
in reality, we are actually measuring larger current decreases and a decrease in collision 
frequency. In other words, this iteration relies on a decrease in detection. So, in theory, 
any phenomenon that might cause PSB agglomeration would effectively result in the 
same output. As such, we continued our studies in a second publication in which MCMV 
particles were enzymatically labeled to generate positive current events (i.e. specific 
increases in current) that were readily differentiated from background non-specific 








Figure 2.4: Frequency vs. concentration for PSBs and PSBs with excess MCMV-
antibody. 
Collisions were counted in amperometry of 100 mM KFCN dissolved in the aqueous 




Figure 2.5: Scanning electron micrographs and optical microscope analogs of equimolar 
amounts of MCMV-antibody and PSBs. 
A-E) Scanning electron micrographs of 0.283 pM PSBs and virus (1:1 stoichiometry), 
examples of n = 1, 2, 3, 4,… aggregates and their optical microscop analogs (F-J) taken 
with a 100X objective lens. In each case, the diameter of the bead was measured to be 













2.2.4 Collisions of Antibody / GOx-coated MCMV  
Previously, we reported the electrochemical detection of murine cytomegalovirus 
(MCMV) collisions on an UME [123]. In this paper, we have extended the collision of 
single viruses to a more specific analytical technique via enzymatic labeling. Glucose 
oxidase (GOx) catalyzes the oxidation of glucose to gluconolactone while reducing an 
oxidant molecule, such as ferrocenium methanol [29]. When oxygen is removed from 
solution, and the oxidation of ferrocene methanol to ferrocenium methanol is carried out 
at the electrode surface, the electrons from the glucose oxidation will reduce ferrocenium 
methanol back to ferrocene methanol, and feedback will be detected at the electrode 
surface, as shown in figure 2.6b [124]. This chemistry is similar to the chemistry used in 
usual glucometers [29]. This local feedback of ferrocene to the electrode surface causes 
an increase in the current response. Because the environmental noise of most 
potentiostats is on the order of 10–100 fA, and a single faradaic enzyme collision is 
capable of generating ca. 0.2 fA of current [125], single faradaic enzyme collisions 
cannot be discerned against the background. Hence, a single enzyme on an electrode 
surface cannot produce enough current to discern against the background. However, by 
covalently attaching GOx to a specific antibody, which in turn binds to the epitope on the 
virus for which the antibody is specific (Figure 2.6a), one can hypothesize that GOx will 
be specifically concentrated on the virus surface. Under these special circumstances, the 
GOx signal is significantly amplified so much so that the signals that are produced able to 
be detected on conventional potentiostats. In doing so, discrete current steps manifesting 
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Figure 2.6: Schematic representation of the CMV virion and corresponding 
antibody/GOx interaction with a surface glycoprotein.  
 
A) Schematic representation of the CMV virion and corresponding antibody/GOx 
interaction with a surface glycoprotein. B) Schematic representation of the antibody and 
GOx conjugate regenerating ferrocene methanol from ferrocenium methanol, the latter of 
which is continuously replenished via oxidation at an electrode surface, in the presence of 





As shown in Figure. 2.7a, the virus itself will nonspecifically adsorb to the 
electrode surface, effectively blocking the redox reaction being carried out. We have 
previously demonstrated this phenomenon using MCMV [123]. Figure 2.7b gives the 
predicted amperometric response for this blocking experiment. In Figure 2.7c, GOx-
labeled anti-gB antibody binds the surface of MCMV in solution, allowing the virus to 
pre-concentrate many enzymes for detection at the electrode surface, greatly amplifying 
the signal of just one GOx enzyme. The predicted amperometric response when the virus 
is surrounded by GOx is shown in Figure 2.7d. If the conjugation is incomplete or the 
antibody is not specific to the virus, no pre-concentration occurs, and blocking will be 
observed, consistent with numerous examples of blocking in the literature [36, 109, 126]. 
When the virus carries enough GOx enzymes to the electrode, feedback is generated, 












Figure 2.7: Schematic representing the predicted blocking and catalytic amplification 
responses. 
 
A) Schematic representation of blocking caused by an MCMV virion. B) Schematic 
representation of the predicted amperometric response when MCMV alone is placed in a 
system containing the electrode, glucose, and ferrocene methanol. C) Schematic 
representing catalytic amplification upon GOx-antibody interaction with MCMV. D) 
Schematic representation of the predicted amperometric response when MCMV-GOx-
antibody collide with an electrode and produce a catalytically amplified current response. 
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Figure 2.8 shows the amperometric i-t (current vs. time) response for the 
collisions of virus after incubation in the antibody/GOx solution in the presence of 1 mM 
ferrocene methanol and 50 mM glucose. As hypothesized (Figure 2.7d), step-wise current 
increases were observed in amperometry. The background current of about 348 pA is 
from the oxidation of ferrocene methanol to ferrocenium methanol. From the 
amperometric response, positive current steps with a slight deactivation are realized 
(anodic current is plotted negatively). The decay of the catalytic current is likely due to 
nonspecific adsorption of organic molecules, such as proteins and/or lipids, onto the 
electrode surface, blocking ferrocene oxidation sites. In the absence of virus, there is not 
enough buildup of GOx to cause a discrete event (Figure 2.9b). The current steadily 
increased over time due to nonspecific adsorption of the GOx/Ab conjugate on the 
electrode surface. No discrete steps were seen because one GOx enzyme is not able to 
generate enough current to manifest as a discrete event. Importantly, MCMV collisions 
with antibody-GOx conjugate without glucose resulted in blocking events only (Figure 
2.9a) and MCMV with glucose and excess GOx resulted in blocking again as there was 
no antibody to facilitate the concentration of GOx around virions (Figure 2.9c). These 
results indicate that all components of the detection system need to be present to visualize 
discrete collision events.  
From previous work by Savéant and coworkers, the current for a single GOx 
enzyme with ferrocenium methanol as the co-substrate to the enzyme is ∼0.2 fA [36, 
125]. The average current step height observed in the reported experiments was 0.8 ± 0.4 
pA, implying that the amount of GOx enzyme on the virus surface is ∼4,000, taking the 
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current produced by one enzyme as 0.2 fA. By estimating the size of the conjugate as a 5- 
to 10-nm
2
, and taking the virus radius to be ∼100 nm, the geometric capacity on the virus 
surface is between 1,300 and 5,000, which agrees with the electrochemical collision 
signal for a single virion. This estimate based on simple geometry does not consider the 
number of epitopes on the virus membrane or steric effects. We cannot completely rule 
out the possibility of the virus aggregating during incubation with the conjugate. From 
our previous study, virus aggregates were observed after adding PSBs functionalized with 
an antibody specific to the FC of the gB antibody,  and we demonstrated that aggregates 
diffuse more slowly compared with free virus, colliding with the electrode at a lower 
frequency [123]. In the studies presented here, current steps on the order of 4–6 pA, 
which could be interpreted as aggregates of virus, were infrequently observed in 
amperometry, occurring only three times in an analysis of over 80 anodic steps. It should 
be noted that these events were not counted during the statistical analysis of the anodic 
steps. Thus, although difficult to directly confirm, the results of our geometric analysis, 
coupled with the analysis of frequency of virus collisions, are consistent with detection of 








Figure 2.8: Amperometric i-t response of the virus in the presence of the antibody/GOx 
conjugate. 
 
The purified virus (MCMV) was incubated with the GOx/antibody conjugate for 30 min 
before experimentation. Measurements were taken in 10 mM PBS, 1 mM ferrocene 
methanol, and 50 mM glucose on a 1-μm-radius Pt UME. The sampling rate for data 








Figure 2.9: Amperometric response to control experiments demonstrating the specificity 
of the presented electrochemical technique. 
 
A) Control amperometric i-t curve of MCMV collisions with the antibody/GOx conjugate 
in the absence of glucose demonstrating blocking. B) Control amperometric i-t curve of 
the antibody/GOx conjugate and glucose. C) Control amperometric i-t curve of MCMV 









2.2.5 Discrimination of MCMV from Murid Gammaherpesvirus 68 (MHV68)  
To demonstrate specific discrimination of MCMV from other particles of similar 
size or morphology, experiments were carried out in the presence of MHV68, a murine 
gamma-herpesvirus related to Epstein–Barr and Kaposi’s sarcoma-associated 
herpesvirus. In the presence of anti-MCMV gB antibody/GOx conjugate, MHV68 shows 
only blocking at the electrode (Figure 2.10a). This indicates that MHV68 does not pre-
concentrate GOx on its surface, because the epitope for Mab 97.3 is specific to MCMV 
gB and is in agreement with our previous work [123]. When MHV68 and MCMV are 
assessed in a mixture of viruses (2:1 MCMV:MHV68) in the presence of GOx–antibody 
conjugate, both blocking and positive current events are observed (Figure 2.10b). 
Because positive current events only occur when MCMV pre-concentrates enough GOx 
by its highly specific antibody interaction, the presence of additional blocking events, 
presumably by MHV68 virions, demonstrates that MCMV can be detected in the 
presence of other viruses or solution species that nonspecifically adsorb to the electrode 
surface. The specificity of the antibody allows for specific positive detection of MCMV 









Figure 2.10: MHV68 can be differentiated amperometrically from MCMV. 
A) Amperometric i-t curve of MHV68 in the presence of the antibody/GOx conjugate 
with glucose in solution and 50 mM PBS. MHV68 blocks the flux of ferrocene methanol 
to the surface of the electrode. (B) Amperometric i-t curve of a mixture of MHV68 and 
MCMV (2:1 MCMV to MHV68) with the antibody/GOx conjugate in a solution of 10 
mM PBS, 50 mM glucose, and 1 mM ferrocene methanol showing positive and blocking 
current responses over the steady-state current level due to the collision of MCMV and 
MHV68, respectively. The steady-state current is the current due to the oxidation of 
ferrocene methanol on a 1-μm-radius Pt UME. 
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2.2.6 Detection of MCMV in the urine of infected mice 
To demonstrate the feasibility of this digital electrochemical collision technique to 
detection of virus in a biological sample, we applied our technique of MCMV detection 
in urine from an infected mouse at various times post-infection. Like its HCMV 
counterpart, MCMV is readily secreted in the urine of infected mice [127]. Figure 2.11a 
gives a schematic representation of the electrochemical immunoassay, and figure 2.11b 
emphasizes the detection of virus in the urine sample. Mice were infected with 10
6
 pfu 
MCMV by intraperitoneal (i.p.) injection, and urine was collected at the indicated times 
post infection. Urine samples were incubated with antibody/GOx and subjected to 
amperometry. Figure 2.11c shows representative results obtained 10 days after the initial 
infection, and discrete positive current steps can be seen with a deactivation. The 
enlarged response shows the step-like nature of the discrete events observed in 
electrochemistry. Experiments with urine from an uninfected mouse (0.5 ml PBS) 
showed no anodic step-like characteristics, indicating that a virus capable of 
concentrating GOx enzymes can only cause the positive anodic step (Figure 2.12a). 
During experiments in urine in the absence of virus, a slow decay in the steady-state 
current was observed. This decay is likely due to non-specific adsorption of proteins and 
other organic species in urine that are not electrochemically active, as evidence by the 
deactivation. Upon collision, a virus covered in GOx will begin reducing ferrocenium to 
ferrocene, providing the feedback loop that gives the positive step in current. Due to 
nonspecific adsorption that is evident in the urine background current decay, likely from 
urea and other organic molecules found in urine, the feedback loop becomes less 
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efficient, as emphasized in the enlarged portion of the amperometric i-t curve in Figure 
2.11c. However, positive current events can be detected in infected mice (Figure 2.12b) 
which demonstrates that this technique can be used to detect viruses in biological 
samples. 
Interestingly, the collision frequency in urine may yield insight into the shedding 
dynamics of the virus as a function of days post infection. In Figure 2.13, the frequency 
of collision is plotted as a function of days post infection. These frequency values are 
averaged from 5 infected mice tracked over the course of two weeks. Although MCMV is 
known to be shed in the urine of infected animals, the kinetics and amplitude of this 
passing during infection are not well characterized. The collision frequencies observed at 
3, 5, 7, 10, and 14 days post infection mimic the viral load dynamics seen in other virally 
infected tissues, like the spleen and liver (see Chapter 3, Figures 3.3a and b). That is, 
there is a peak viral load reached and then subsequent clearance. As such, the 
electrochemical detection methodology proposed here may yield insight into the secretion 
of virus into the urinary system. Interestingly, the collision frequency observed on day 5 
implies that the limit of detection is about 30 fM (femtomolar) of viral particles relying 








Figure 2.11: Workflow for MCMV detection in the urine of mice infected with MCMV. 
 
A) Schematic representation of the electrochemical immunoassay. B) Enlargement of the 
assay emphasizing the detection of virus. C) Representative amperometry of 50 μL urine 
diluted with 400 μL of 1 mM ferrocene methanol and 100 mM glucose with a 








Figure 2.12: Representative amperometric i-t responses of mouse urine mixed with 
ferrocene methanol, glucose, and the GOx/antibody conjugate from uninfected on 
infected mice. 
 
A) Amperometric i-t curve of representative uninfected mouse urine. The gradual 
decrease in the current response at the electrode is likely due to fouling of the electrode 
due to various organic molecules (e.g. urea, etc.) present in urine. B) Amperometric i-t 
curve of representative infected mouse urine. Discrete collision events are observed in the 











Figure 2.13: Frequency of collision versus day post infection of infected mouse urine. 
 
Five C57Bl6/J mice were infected with 10
6
 PFU of WT MCMV and urine was collected 
from individual mice over the course of 2 weeks. Collision frequencies from each of the 
urine samples from a given day post infection were averaged and plotted as a function of 





Facile, rapid diagnostic methods are essential for proper and expedient treatment 
for any number of infectious diseases. Electrochemical methods provide researchers with 
several avenues along which diagnostic instruments can and have been developed. For 
example, glucose meters, critical for diabetes patients to monitor blood glucose levels, 
utilize chemistry very similar to that described above [29]. Additionally, electrochemical 
methods have been developed and used for the monitoring of levels of various organic 
molecules, pesticides, antibiotics, and a number of bacterial pathogens in and on the food 
we eat [32]. While these methods are quite sensitive, we report the first instance of 
utilizing collision electrochemistry for the specific detection of a single viral particle 
from infected animals. 
    While collision electrochemistry has proven itself to be a powerful tool for the 
study of single molecules or particles [37], the method itself is not able to readily 
differentiate between the collisions of different species in a complex mixture. For this 
reason, specificity measures need to be taken in order to utilize this sensitive technology 
for the detection of particles of interest. In the case of pathogen detection by 
electrochemistry, biology offers a unique set of tools so that specificity may be reached.  
Upon infection, pathogens, like cytomegalovirus, will ultimately elicit the 
adaptive immune response. One important arm of this response is the generation of high 
affinity antibodies that recognize the pathogen and increase the likelihood of clearance 
from the infected host by a variety of different mechanisms [128]. One such antibody 
usually generated recognizes an epitope in the viral glycoprotein known as gB. The same 
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is true for the mouse cytomegalovirus, MCMV. In addition to serving important roles in 
neutralizing infection, researchers can use these antibodies in the laboratory to learn more 
about the virus. In the stories described above, an MCMV gB antibody capable of 
neutralizing MCMV was utilized for the specific detection of MCMV in the presence of 
another virus as well as in the urine of infected mice. This detection was made possible 
by the covalent attachment of GOx to the antibody.  
While the first method relies on a decrease in collision frequency and an increase 
in current step size, the second method provides an even more sensitive positive detection 
result by utilizing the chemistry of glucose oxidase. Generation of a constant flux of 
ferrocene methanol by glucose oxidase to be oxidized at the electrode causes discrete 
current steps where current momentarily increases before settling to a new steady state. 
While a signal to noise ratio of about 15:1 was generated using this methodology, greater 
current step sizes would be ideal in order to definitively conclude a collision event 
resulting in a current increase occurred. In other words, greater signal amplification is 
needed gain even more sensitivity and to reduce the possible rate of false positives. 
Additionally, sensitivity can be gained by optimizing the limit of quantitation. This can 
be done by introducing some sort of microfluidics, in which virus / antibody-GOx 
conjugates are reliably directed to an electrode or electrode array. This may increase 
detection and would potentially allow for the quantification of a given virus’ 
concentration in solution (i.e. # collisions / unit volume passed / second). These 
possibilities are discussed in greater detail in Chapter 4.  
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While electrochemical analyses have been applied to the detection of a number of 
different pathogens (food pathogens, etc), we report the first specific digital pathogen 
detection scheme using collision electrochemistry. As detection methodologies improve 
and better point-of-care diagnostics are developed for pathogens, an equal effort needs to 
be taken for development of better treatment options. In the case of HCMV infection, 
current antiviral therapies can be very toxic. Additionally, clinical isolates of HCMV 
have demonstrated resistance to antiviral drugs. As such, novel, unique viral targets for 
drug treatment need to be identified and characterized to determine their promise as 
druggable targets. In the next chapter, we describe work that characterized a uniquely 
structure and highly conserved MCMV deubiquitinating enzyme and propose that it may 








Chapter 3: Murine cytomegalovirus deubiquitinase regulates viral 
chemokine levels to control inflammation and pathogenesis2 
3.1 INTRODUCTION 
The prototypic beta-herpesvirus, human cytomegalovirus (HCMV), remains a 
major causative agent of nongenetic birth defects, such as sensory loss, defects in neural 
development, and microcephaly [129]. Although immunocompetent patients typically 
present no obvious symptoms of infection, HCMV still represents a major cause of 
morbidity and mortality in immunocompromised or immunonaive individuals, including 
transplant recipients and infants infected prenatally [129]. In order to navigate the 
multitude of antiviral responses in an immunocompetent host, cytomegaloviruses devote 
a significant portion of their genome to counteracting or appropriating host responses to 
facilitate successful infection [130, 131]. HCMV encodes a number of proteins involved 
in various processes, such as type I interferon (IFN) [13, 132-134], cell death pathways 
[135], and major histocompatibility complex class I antigen presentation [136], that act to 
antagonize or appropriate antiviral responses. In addition to intracellular immune 
modulation, cytomegaloviruses encode cytokines and chemokines to modulate immune 
responses at a distance [137]. 
Due to the high degree of species specificity, tractable model systems are required 
for host/pathogen studies of the cytomegaloviruses. The use of the murine 
cytomegalovirus (MCMV) model system has provided significant insight into CMV 
                                                 
2 Large portions of this chapter have been previously published.  
1. Hilterbrand AT, Boutz DR, Marcotte EM, Upton JW. 2017. Murine Cytomegalovirus 
Deubiquitinase Regulates Viral Chemokine Levels to Control Inflammation and Pathogenesis. 
mBio 8(1): e01864-16. 
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biology over the years [138]. HCMV and MCMV share significant genetic and biological 
characteristics; among them is the large tegument protein (LTP). This essential protein 
[70, 139, 140] encodes a structurally distinct deubiquitinase within its amino terminus 
[89]. Though not essential for replication [75, 85, 97, 141], the DUB activities possessed 
by LTPs in other herpesviruses have been ascribed a number of distinct functions. 
Emerging evidence suggests that herpesvirus DUBs play roles in manipulating 
host antiviral responses to infection. Murine gammaherpesvirus 68 (MHV 68) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV) DUBs can deubiquitinate RIG-I, thus 
removing its ability to signal to downstream components and propagate type I IFN 
signaling [83]. The herpes simplex virus 1 (HSV-1) DUB, UL36, can target tumor 
necrosis factor (TNF) receptor-associated factor 3 (TRAF3), thereby blocking type I IFN 
production [72]. The Epstein-Barr virus (EBV) DUB, BPLF1, blocks NF-κB signaling 
via the deubiquitination of several proteins involved in Toll-like receptor (TLR) 
signaling, namely, TRAF6, NEMO, and IκBα [95]. Recent work also demonstrated a 
conserved function for herpesvirus DUBs in antagonizing stimulator of interferon gene 
(STING)-dependent interferon responses in bone marrow-derived dendritic cells 
(BMDCs) [87], further implicating herpesvirus DUBs in the modulation of antiviral 
signal transduction. 
Additionally, several herpesvirus DUBs have been ascribed roles in pathogenesis. 
The DUB of pseudorabies virus (PRV) targets itself for deubiquitination, allowing 
transmission to nerve termini and subsequent axonal retrograde transport to facilitate 
neuroinvasion [77]. Inactivation of the Marek’s disease virus (MDV) DUB led to a 
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decrease in lymphoma incidences in chickens [80]. Moreover, an MHV 68 DUB mutant 
showed rapid clearance from infected spleens [86] and a decrease in the establishment of 
STING-dependent latency [87]. Those studies indicated that herpesvirus DUBs contribute 
to replication and pathogenesis in their hosts. Recent work has also shown that the 
HCMV DUB is active during infection, contributes modestly to replication, and 
maintains virion stability and infectivity [97, 98]. However, in vivo analyses examining 
the contribution of CMV DUB activity to replication in a live host have not been 
conducted. In this report, we show that the MCMV DUB, M48, significantly contributes 
to the replication and dissemination of MCMV in vivo by regulating levels of MCK2, the 
virally encoded proinflammatory chemokine. In regulating MCK2 levels, aspects of 
MCK2 biology, namely, MCK2-dependent inflammatory responses and incorporation of 
MCK2 into virions, are also controlled. Interestingly, concomitant loss of MCK2 in the 
presence of a mutant DUB restored replication in most cell types in culture as well as in 
the spleen and liver of infected mice. These results highlight MCMV DUB contributions 
to acute infection in vitro and in vivo and provide important mechanistic insight into the 
role that it plays during infection in a natural host. It appears that MCK2-dependent 
responses are managed through DUB-dependent regulation of MCK2 levels. 
3.2 RESULTS 
3.2.1 MCMV DUB activity contributes modestly to replication in cell culture 





 was generated by 2-step allelic exchange mutagenesis of 
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the pARK25 bacterial artificial chromosome (BAC) containing the K181 Perth strain of 
MCMV by first inserting a selection/counterselection cassette (SacB/Kan
r
[kanamycin 
resistance]) into the open reading frame of M48. The catalytic cysteine of the M48 DUB 
was then replaced with a serine residue (Figures 3.1a and 3.2a). This mutation was 
repaired to restore the wild-type (WT) sequence by allelic exchange to control for 
spurious distal mutations, generating the MCMV-M48
Rep
 virus, which behaved similarly 
to WT virus in vivo (Figures 3.2e and f). Importantly, the C23S mutation was sufficient to 
inactivate M48 DUB activity (Figure 3.2d). To begin the characterization of MCMV-
M48
C23S
, we first sought to determine the contribution of MCMV M48 DUB activity to 
viral replication in culture. Single-step growth analyses of infected cells in culture 
revealed that MCMV-M48
C23S
 is modestly attenuated for growth in fibroblasts 
(Figure 3.1b) and endothelial cells (Figure 3.1c) compared to WT or the M48
Rep
 viruses. 
In contrast, mutant and control viruses replicated similarly in a macrophage cell line 
(Figure 3.1d), suggesting a potential cell type-specific role for DUB activity during lytic 
replication. Multistep growth of the mutant virus displayed similar levels of attenuation 
in all 3 cell types (Figure 3.1e-g). Together, these results reveal that M48 DUB activity 
plays a minor role in viral replication that is similar to the role ascribed to the DUB 
activity of the HCMV homologue, UL48 [97]. 
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Figure 3.1: M48 DUB activity contributes modestly to replication in cell culture. 
A) Schematic of the genomic location of and mutagenesis performed in the MCMV 
DUB, M48.  B-G) Single-step (B to D) (MOI = 5.0) and multistep (E to G) (MOI = 0.05) 
growth curves in NIH3T3 fibroblasts (B and E), SVEC4-10 endothelial cells (C and F), 
or RAW264.7 macrophages (D and G). Each data point represents n >6 replicates. The 0 
h time point represents the time immediately post wash and addition of fresh complete 










A) Schematic diagram depicting the genomic area around M48 as well as the 
mutagenesis strategy. Numbers represent MCMV genomic coordinates (GenBank 
accession number AM886412.1), and abbreviations indicate restriction enzymes sites (Hi, 





 generation. B) Restriction fragment length 
polymorphism analysis of WT, M48SK-1, M48
C23S
, M48SK-2, and M48
Rep 
bacterial 
artificial chromosomes with EcoRI restriction enzyme. C) BamHI digest of PCR-
amplified region surrounding the C23S mutation in which synonymous mutations were 
introduced generating a unique BamHI restriction site. Taqα1digestion was performed to 
show that surrounding sequence was not affected. Amplicons were also sequenced by 





. 24 hours post transfection, cell lysates 
were collected and immunoblot analysis was performed for the presence of ubiquitin 
conjugates. E and F) Splenic (E) and liver (F) titers for WT and M48
Rep 
virus were 
assessed to demonstrate that the repair virus replicated like its WT counterpart. 
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3.2.2 MCMV DUB activity is critical for replication in mice, and a mutant DUB 
virus elicits a greater inflammatory response 
 
We next sought to determine the contributions of M48 DUB activity to replication 





 virus by intraperitoneal (i.p.) injection. Acute replication in spleen, liver, 
and salivary glands was assessed at the indicated times postinfection. Compared to the 
repaired virus, MCMV-M48
C23S
 was severely attenuated for acute replication in all 
organs assessed. Although replication of both mutant and repaired virus in the spleens of 
infected mice peaked at 5 days postinfection, MCMV-M48
C23S
 replication achieved peak 
levels 24-fold lower than those seen with MCMV-M48
Rep
 (Figure 3.3a). Viral titers in 
infected livers (Figure 3.3b) revealed that MCMV-M48
C23S
 replicated at or slightly above 
the limit of detection and displayed no obvious peak of replication, whereas MCMV-
M48
Rep
 replicated to the expected levels in this organ [142]. MCMV-M48
C23S
 was 
detected in the salivary glands of animals by 14 days postinfection; however, the levels 
were approximately 240-fold lower than those seen with MCMV-M48
Rep
 (Figure 3.3c). 
Together, these results show that the DUB function of M48 is critical for MCMV 
replication in a natural host. 
We continued our in vivo characterization of MCMV-M48
C23S
 by examining the 





. Footpad inoculation allows the assessment of virus-induced 
inflammation at the site of inoculation, characterized by swelling of the infected footpad. 
Surprisingly, MCMV-M48
C23S
 caused a rapid onset of swelling by 3 days postinfection 
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not seen in the MCMV-M48
Rep
 virus-infected mice (Figure 3.3d). Thus, despite being 




Figure 3.3: MCMV DUB activity is critical for replication in mice, and a mutant DUB 
virus elicits a greater inflammatory response. 







. Spleen (A), liver (B), and salivary gland 
(C) were collected and assessed at the indicated days post infection (d.p.i.). Each data 
point represents an n > 5 mice. D) Footpad swelling of C57BL6/J mice infected with 10
6
 




 via footpad injection. Swelling was 
measured by digital caliper over the course of 14 days, and data are plotted as percent 




3.2.3 M48 DUB activity regulates MCK2 levels and can regulate secretion 
As MCMV-induced swelling is influenced by the production of the MCMV-
encoded C-C chemokine, MCK2 [143-145], we next investigated what role the DUB 
activity of M48 may play in regulating this chemokine. As swelling occurred rapidly in 
the footpads of MCMV-M48
C23S
-infected mice, we hypothesized that MCK2 levels may 
be increased in MCMV-M48
C23S
-infected cells. In order to test this, NIH3T3 fibroblasts 
were infected (multiplicity of infection [MOI] = 5.0) and lysates collected at 0, 12, 24, 





-infected fibroblasts revealed elevated MCK2 
levels in MCMV-M48
C23S
-infected fibroblasts compared to the WT-infected or MCMV-
M48
Rep
-infected fibroblasts (Figure 3.4a). The levels of other representative immediate-
early (IE1), early (E1), and late [M86/major capsid protein (MCP)] viral gene products 
were similar between the viruses during infection. These results suggest that M48 DUB 
activity negatively regulates MCK2 levels during infection. 
To further test this hypothesis and assess the potential modulation of MCK2 by 
M48 DUB activity, M48 (WT or C23S) and MCK2 were cloned into the expression 
vectors pEGFP-N1 and p3XFLAG-CMV-14, respectively, and cotransfected into 
NIH3T3 murine fibroblasts. To directly address the effect of M48 DUB activity in 
regulating MCK2 secretion in the absence of infection, MCK2 was immunoprecipitated 
(IP) from the supernatants of cells cotransfected with epitope-tagged MCK2 and 
enhanced green fluorescent protein (EGFP)-tagged WT M48 or M48
C23S
 expression  
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constructs. While MCK2 exhibited low levels of secretion in samples transfected with 
MCK2 alone, cotransfection with either M48 or M48
C23S
showed elevated levels of 
MCK2 in the supernatant (Figure 3.4b). Interestingly, MCK2 secretion was reproducibly 
higher in cells cotransfected with M48
C23S
, consistent with a model in which the M48 
gene product promotes secretion of MCK2, and the DUB activity of M48 negatively 
regulates this process. Immunoblot analysis of cell lysates coexpressing MCK2 and WT 
M48, but not M48
C23S
 or EGFP alone, showed marked accumulation of an ~30-kDa band 
corresponding to the unglycosylated form of MCK2 [146] (Figure 3.5a), suggesting that 
M48 DUB activity stabilizes or promotes accumulation of unglycosylated MCK2. This 
accumulation may result from a block of proteosomal degradation of MCK2, as 
evidenced by the accumulation of the unglycosylated 30-kDa band following a 
cycloheximide chase with MG132 pretreatment (Figure 3.5b). These results suggest that 
MCK2 expression may be controlled by endoplasmic reticulum-associated protein 
degradation (ERAD) and that M48 DUB activity prevents MCK2 proteasomal 
degradation after retrotranslocation from the ER. An important constituent of the ERAD 
process is the AAA ATPase, p97/VCP, which extracts proteins from the ER in an ATP-
dependent fashion and facilitates their ultimate degradation by the proteasome [147]. 
Overexpression of a dominant-negative p97 (p97
QQ
) blocks retrotranslocation of proteins, 
such as the Rem signal peptide of mouse mammary tumor virus (MMTV), from the ER 
[148]. Consistent with a role for ERAD in regulating MCK2 expression, cells 
cotransfected with p97
QQ
 showed a significant increase in MCK2 secretion (Figure 3.5c).  
This result is similar to the observed increase in MCK2 secretion in the presence of M48,  
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regardless of the presence or absence of DUB activity (Figure 3.4b). Together, these 
results (Figures 3.4 and 3.5) show that M48 plays DUB-dependent and -independent roles 
in the control of MCK2. Furthermore, they suggest that M48 may modulate ERAD or 
ERAD substrates like MCK2 to influence expression and secretion from infected cells 
and that this process is subject to fine control by M48 DUB activity. 
 78 
 
Figure 3.4: M48 DUB activity regulates MCK2 levels and can regulate secretion. 





 (MOI = 5.0). Samples were collected at 
the indicated times post infection, and levels of MCK2, as well as those of representative 
immediate early (IE1), early (E1), and late [M86 (MCP)] viral antigens, were detected by 
immunoblotting. β-actin served as a loading control. B) Immunoblot (IB) analyses of 
supernatant immunoprecipitations (IP) (top panels) or whole-cell lysates (bottom panels) 
from NIH3T3 fibroblasts transfected with the indicated plasmids. At 24 hours post 
transfection, cell culture supernatants were collected and subjected to anti-FLAG 
immunoprecipitation as described in the Materials and Methods. Cells were collected at 
the same time, and lysates were generated and proteins separated by SDS-PAGE. 
Samples were immunoblotted with the indicated antibodies. Data are representative of 





Figure 3.5: MCK2 levels and secretion are controlled by ERAD. 
A) NIH3T3 cells were transfected with EGFP, M48, or M48
C23S
 and with pCDNA3.1 
(EV) or MCK2. Immunoblot analysis was performed on whole-cell lysates (both 
untreated and treated with PNGase F). B) NIH3T3 cells were transfected with MCK2 and 
then subjected to pretreatment with either dimethyl sulfoxide (DMSO) or MG132 (20 
μM) 24 hours post transfection for 1 hour prior to the addition of cycloheximide (CHX) 
(100 μg/ml). Whole-cell lysates were collected at 0, 4, 8, 12, and 24 hours post-CHX 
treatment, and MCK2 was subjected to immunoblot analysis. *, unglycosylated MCK2 
product. C) NIH3T3 cells were transfected with MCK2 and pCDNA3.1 empty vector 
(EV), 6-His p97
WT
, or 6-His p97
QQ






3.2.4 M48 DUB activity controls MCK2 incorporation into mature virions 
In addition to serving as a chemokine during infection, MCK2 can also associate 
with the glycoprotein H/glycoprotein L (gH/gL) complex in mature virions. 
gH/gL/MCK2 glycoprotein complexes promote pH- and energy-dependent entry and 
facilitate entry into macrophages [149]. To determine if M48 DUB activity had an effect 
on virion-associated MCK2 levels, cell-free virions were purified by gradient 
centrifugation and subjected to immunoblot analysis. MCMV-M48
C23S
 virions contained 
higher MCK2 levels than MCMV-M48
Rep
 virions, while M86 (MCP) levels remained 
constant between samples (Figure 3.6a). Mass spectrometry (MS)-based proteomics 
analysis of purified virions confirmed these findings. Label-free relative quantitation 
consistently showed higher levels of MCK2 protein in MCMV-M48
C23S
 virions than in 
MCMV-M48
Rep
 virions (Figure 3.6b), indicating that, in addition to controlling MCK2 
levels during infection, M48 DUB activity controls the amount of MCK2 incorporated 
into infectious virions. Interestingly, the MCK2 partner M115 (gL) also showed a modest 
and yet statistically significant increase in abundance, suggesting that MCK2 and gL may 
share a pathway for maturation and assembly regulated by the DUB. In contrast, no 
changes were observed in the relative levels of the major fusogenic glycoprotein M55 
(gB) or of the components of the gM/gN glycoprotein complex, M100 (gM) and M73 
(gN) [150] (Figure 3.6b). 
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Figure 3.6: M48 DUB activity controls MCK2 incorporation into mature virions. 




 virions purified over 
a 20% to 70% linear sorbitol gradient. Equal amounts of virion lysate were loaded and 
MCK2 levels were assessed by immunoblotting. M86 (MCP) served as a loading control 
between samples. B) Relative peptide abundances of virion-associated glycoproteins M55 
(gB), MCK2, M75 (gH), M115 (gL), M74 (gO), M100 (gM), and M73 (gN) in purified 
MCMV-M48
C23S
 virions compared to MCMV-M48
Rep
. Ratios were calculated as 
averages of target ion peak areas normalized to M86 (MCP) for three independent 
experiments. Error bars represent standard errors of the means. **, P < 0.01; ***, P < 






3.2.5 Deletion of MCK2 rescues MCMV-M48
C23S 
replication in vitro and in vivo 
Given our results suggesting that M48 DUB activity controls MCK2 protein 
levels, we hypothesized that the MCMV-M48
C23S
 attenuation was at least partly due to 
the greater amounts of MCK2 being produced. If so, genetic ablation of MCK2 would 
restore replication of the DUB mutant virus. To directly test this hypothesis, two 
additional recombinant viral mutants were constructed. Both the WT and M48
C23S
 viruses 
were modified by introducing a translational stop and a single-nucleotide frameshift 







 (Figures 3.7a, 3.8a-c). In order to confirm a loss of MCK2 expression, 
gradient-purified virions were subjected to immunoblot analyses, with the results clearly 







 was initiated 
with single-step and multistep growth analyses in cell culture for NIH3T3 fibroblasts, 
SVEC4-10 endothelial cells, and RAW264.7 macrophages. Surprisingly, the single-step 







no difference in replication kinetics in fibroblast and endothelial cell lines (Figure 
3.7c, d, f, and g), suggesting that the modest replication defect for MCMV-
M48
C23S







 replicated similarly in single-step replication 





remained modestly attenuated during multistep replication (Figure 3.7h). This result is  
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similar to that shown in Figure 3.1g, where MCMV-M48
C23S
 replicated at titers 4-
fold to 5-fold lower than MCMV-M48
Rep
 or WT MCMV, suggesting that DUB-
dependent functions may govern replication in macrophages independently of MCK2. 
To further investigate the role of MCK2 dysregulation in MCMV-
M48
C23S
replication in a natural host, animals were infected with Mck2-deficient viruses 
by i.p. injection. Concomitant loss of MCK2 reversed the acute replication defect of 
MCMV-M48
C23S
 to WT levels in spleen and livers of infected mice over a time course of 
14 days postinfection (Figure 3.9a and b). Mck2-deficient viruses were not detected in 
salivary glands of infected mice (Figure 3.9c), consistent with a role for MCK2 in virus 
dissemination. To determine if the rapid onset of footpad swelling was dependent on 














 showed identical levels of swelling and recovery over the 14-
day time course with no rapid onset of swelling (Figure 3.9d) as seen in the MCMV-
M48
C23S
-infected mice (Figure 3.3d). This suggests that the DUB-dependent swelling 
phenotype observed in MCMV-M48
C23S
-infected mice (Figure 3.3d) was mediated by 
MCK2. Taken together, these results indicate that M48 DUB activity regulates MCK2 
biology by controlling its expression, maturation, or secretion during infection. 
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Figure 3.7: Concomitant loss of MCK2 rescues MCMV-M48
C23S
 replication in culture. 
 
A) A schematic representing the genomic location and generation of mutant viruses 






). B) Immunoblot of gradient-
purified virions of the indicated genotype to confirm loss of MCK2 expression. C to H) 
Single-step (C-E) (MOI = 5.0) and multistep (F-H) (MOI = 0.05) growth curves in 
NIH3T3 fibroblasts (C and F), SVEC4-10 endothelial cells (D and G), or RAW264.7 
macrophages (E and H). Each data point represents n = 3 biological replicates.  
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Figure 3.8: Generation of viruses lacking MCK2 expression. 
 
A) Schematic diagram depicting the genomic area around MCK2 (m129-m131) as well 
as the mutagenesis strategy to generate MCK2-deficient viruses. Numbers represent 
MCMV genomic coordinates (GenBank accession number AM886412.1) and 
abbreviations indicate restriction enzyme sites (Hi, HindIII; Ec, EcoRI; Ba, BamHI). See 


















 BACs digested with EcoRI. C) Amplicons from M48 and m131 









showed digestion by BamHI. An MseI restriction site introduced into m131 in the form 




Figure 3.9: Concomitant loss of MCK2 in the presence of the DUB mutation rescues 
MCMV-M48
C23S
 replication in the spleens and livers and ameliorates footpad swelling. 
 
A-C) C57BL6/J mice were infected with 10
6







 via i.p. injection. Viral load in the spleens (A), livers (B), and salivary 
glands (C) was assessed at the indicated times post infection. Each data point represents n 
> 5 mice. D) Footpad swelling of C57BL6/J mice infected with 10
6







 via footpad injection. Swelling was 
measured by digital caliper over the course of 14 days, and data are plotted as percent 




In this report, we describe a systematic investigation into the role of the MCMV 
DUB in vitro and in vivo. Specific mutation of a catalytic cysteine within the DUB 
domain of M48 (C23S) revealed a minor role for M48 DUB activity in MCMV 
replication in cultured cells (see Figure 3.1b-g) but substantial attenuation in a natural 
host (Figure 3.3a-c). Importantly, these results are consistent with previous reports 
demonstrating that the DUB activity of the HCMV orthologue of M48, UL48, is present 
during infection and modestly contributes to replication in cell culture [97]. Interestingly, 
our work revealed that a major role for M48 DUB activity is control of MCK2, the viral 
chemokine, both in vitro and in vivo. Loss of M48 DUB function results in increased 
MCK2 levels (Figure 3.4a), manifesting as enhanced inflammation at localized sites of 
infection in mice (Figure 3.3d) and resulting in attenuation of MCMV replication 
(Figures 3.3a-c and 3.9a and b). Concomitant loss of MCK2 restored most observed 
DUB-dependent phenotypes in vitro and in vivo (Figures 3.7 and 3.9), providing 
compelling genetic evidence for a mechanism of intrinsic control over the virus-encoded 
chemokine. 
Accumulating evidence implicates cellular DUBs in the control of a number of 
host proinflammatory pathways. The host deubiquitinase, A20, is critical for regulating 
NF-κB activation and subsequent activation of proinflammatory cytokines [151, 152]. 
Additionally, recent work has shown that the cellular DUB, Trabid, negatively regulates 
expression of interleukin-12 (IL-12) and IL-23 via the modification of ubiquitinated  
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histones [153]. OTULIN, the Met1-linked deubiquitinase, controls levels of Met1-linked 
ubiquitin chains, modulating activation of NF-κB responses and TNF-α levels [154]. 
While herpesvirus DUBs have been implicated in the control of host inflammatory signal 
transduction [72, 83, 95], M48 appears unique in that it manages levels of MCK2, a 
virally encoded chemokine. While our results do not exclude the possibility that M48 
DUB activity may regulate other pathways, they provide the first example of a 
herpesvirus DUB controlling levels of a viral chemokine. 
In order to determine whether MCK2 production contributed to the observed 
phenotypes of the MCMV-M48
C23S
 virus, we took a genetic approach and ablated MCK2 
expression. Surprisingly, concomitant loss of MCK2 in the presence of the mutant DUB 
restored replication in most cell types in culture (Figure 3.7c-h). Fibroblasts and 







similar replication kinetics in single-step and multistep replication analyses. Although the 
mechanism of attenuation of MCMV-M48
C23S
 in fibroblast and endothelial cells is likely 
complex, recent findings suggest that increased levels of virion-associated MCK2 
(Figure 3.6a and b) promote an endocytic mode of entry over fusion at the plasma 
membrane [149]. Endocytic entry of herpesviruses results in delayed gene expression and 
increased antiviral gene transcription [155], both of which could contribute to attenuation 
of virus replication. Increased levels of these antiviral proteins may occur in MCMV-
M48
C23S
-infected cells, resulting in modest attenuation. We have recently shown that 
MCMV-M48
C23S
 elicited a greater stimulator of interferon gene (STING)-dependent type  
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I IFN response in cultured dendritic cells [87]. However, whether virion-associated 
MCK2 levels and STING-dependent responses during infection are connected remains to 
be determined. 
Interestingly, while no difference in replication was observed in single-step 
growth kinetics on macrophages (Figure 3.7e), loss of MCK2 in the presence of the 
mutant DUB failed to alleviate the modest growth defect in multistep growth 
(Figure 3.7h), similarly to that seen in Figure 3.1g. These results imply that DUB-
dependent, MCK2-independent mechanisms may be necessary for efficient replication in 
macrophages. Since macrophages and monocytes are important CMV target cells in vivo, 
a potential role for DUB-dependent functions in cell tropism warrants further 
investigation. 
Surprisingly, replication of MCMV-M48
C23S
 in the spleens and livers of infected 
mice was restored with targeted deletion of MCK2. Previous work examining the 
contributions of MCK2 to pathogenesis has shown that, while MCK2 is necessary for 
dissemination to the salivary glands, it is dispensable for replication and spread in the 
spleen and liver [144, 145, 156]. Our results are consistent with these findings showing 
that MCK2 is not a major contributor to the early stages of infection in target organs. We 
extend these observations to show that overproduction and/or dysregulation of MCK2, as 
seen in MCMV-M48
C23S




MCK2 is necessary for effective dissemination of MCMV to the salivary glands 
of infected mice [144, 145, 157, 158]. However, MCMV-M48
C23S
, which fails to 
appropriately control MCK2 production or secretion, remained impaired for 
dissemination to the salivary glands regardless of the route of inoculation (Figures 
3.9c and 3.10). Thus, it is tempting to speculate that careful calibration of MCK2 levels 
facilitates a successful infection. Recent work utilizing recombinant MCMVs expressing 
viral or mammalian neutrophil-attracting chemokines (mouse CXCL1 or HCMV 
CXCL1) showed that overexpression of pro-inflammatory chemokines is detrimental to 
MCMV dissemination to the salivary gland [159]. Our work is consistent with those 
findings in that uncontrolled MCK2 levels impair dissemination of MCMV. However, as 
expected, neither the MCMV-m131
stop




 viruses were reliably 
detected in the salivary glands of infected mice (Figure 3.9c), indicating that MCK2 is 
required for dissemination. Thus, it is difficult to conclude that MCK2 overproduction is 
the only contributor to a decrease in mutant DUB virus dissemination. DUB-dependent, 
MCK2-independent contributions to MCMV dissemination and/or salivary gland 
replication may exist. The modest replication defect seen in multistep replication kinetics 
in macrophages (Figures 3.1g and 3.7h) could indicate the existence of DUB-dependent 






Figure 3.10: Salivary gland titers from mice infected via a footpad (f.p.) route of 
inoculation. 
 
The salivary glands from the f.p.-infected mice in Figures 3.3a-c and 3.9a-c were 













 virus, distinct differences manifest in two 
viral proteins (Table 3.1). Specifically, viral proteins sgg1 and m137 are elevated in 
MCMV-M48
Rep 
infected cells compared to MCMV-M48
C23S
 infected cells. While the 
specific functions of m137 are unknown, aside from the fact that it appears to contribute 
to virulence [160], sgg1, or salivary gland growth gene 1, has been shown to be critical 
for replication in the salivary glands of infected mice [161]. Sgg1 is a virally encoded 
type 1 transmembrane protein encoded by the m133 open reading frame of MCMV [162]. 
Sgg1 is not essential for replication in cell culture or in many organ types in mice. 
However, sgg1 is critical for replication in the salivary gland. It is important to note that 
sgg1 does not contributing to the dissemination of MCMV to the salivary glands, but is 
responsible for MCMV replication in the acinar cells of infected salivary glands [163], 
though the exact mechanism by which it mediates this is currently unknown. While we 
originally hypothesized that MCMV-M48
C23S
 attenuation may be due to increased levels 
of MCK2, these results suggest another DUB-dependent mechanism in governing the 





 infected cells (Figure 3.4a). These data 
suggest that M48 DUB activity utilizes different mechanisms to control the levels of 




Table 3.1: Peptide spectrum matches (PSMs) of sgg1 and m137 from infected fibroblasts. 
NIH3T3 cells were infected at an MOI = 5.0 and lysates were collected 48 hours post 
infection. Peptides were prepared (see materials and methods) and subjected to LC-





















In addition to attenuation of acute replication, MCMV-M48
C23S
 induced a robust 
inflammatory response following footpad inoculation. We showed that this phenotype is 
restored to WT levels by concomitant loss of MCK2 (Figure 3.9d). This result clearly 
indicates that the rapid swelling observed in MCMV-M48
C23S
-infected mice was due to 
MCK2 overproduction. Unlike previous footpad studies performed with MCK2-null 







. This inconsistency may be 
due to several factors. In previous works, the K181+ strain and its MCK2 mutant 
derivatives were used, while our studies utilized the BAC-derived K181 Perth strain 
(pARK25) of MCMV. Additionally, most studies of MCK2-dependent inflammation 
have employed BALB/c mice, whereas we report results from C57BL/6 mice. While the 
source of these differences in the results of control experiments warrants further 
investigation, we clearly demonstrated that the rapid swelling seen in MCMV-M48
C23S
-
infected mice is ameliorated by ablating MCK2 expression. This is compelling evidence 
that loss of DUB control over MCK2 expression, maturation, or secretion mediates the 
inflammatory phenotype of MCMV-M48
C23S







Although the specific substrate(s) of M48 DUB activity during infection remains 
unknown, we anticipate that significant targets include endoplasmic reticulum- and/or 
Golgi-associated components. Interestingly, the M48 homologue encoded by HCMV, 
UL48, has been shown to interact with the endoplasmic reticulum protein RRBP1/ES130 
[164], a ribosome binding protein critically implicated in the function of the secretory 
pathway [165, 166]. Although the functional relevance was not addressed, considered 
together with the data reported here, a possible model emerges wherein beta-herpesvirus 
DUBs may be localized to the ER, allowing control over secreted or transmembrane 
protein maturation, whether host or virus in nature. This association at the ER might 
allow M48 to affect secretory events via RRBP1 by modulating ERAD, or through 
another currently unknown mechanism (Figure 3.13). While it is unknown whether M48 
itself interacts with any ER-resident proteins, fluorescence microscopy shows that WT 
M48 localizes in a very perinuclear fashion. Interestingly, mutant DUB M48 seems to 
localize in a more diffuse pattern when compared to WT M48 (Figure 3.11). This 
difference in localization may lead to a difference in interacting partners, and 








Figure 3.11: Fluorescence imaging of M48 and M48
C23S
 localization in uninfected cells. 
A-C) NIH3T3 cells were transfected with either and eGFP expression vector (A), M48-
eGPF (B), or M48
C23S
-eGFP (C). 24 hours post transfection, cells were fixed, 
permeabilized, and counterstained with Hoechst stain. Cells were imaged on an EVOS 

















Figure 3.12: MCK2 ubiquitination in the presence of M48. 
NIH3T3 cells were co-transfected with M48-eGFP, MCK2-3XFLAG, and HA-Ub. 24 
hours post transfection, lysates were collected and subjected to anti-HA 








While we do not know what the direct targets of M48 DUB activity are at this 
time, we have begun to rule out some possible candidates. One obvious candidate is 
MCK2 itself; i.e. is MCK2 a direct target of M48 DUB activity. Interestingly, MCK2 
does not appear to be a primary target of M48 deubiquitination. In cells co-transfected 
with M48-eGFP, MCK2-3XFLAG, and HA-Ubiquitin, MCK2 is more heavily 
ubiquitinated than cells co-transfected with eGFP, MCK2 and HA-Ubiquitin (Figure 
3.12). While not indicative of any cellular targets of M48 DUB activity, these results do 
suggest that the DUB is not directly modulating the ubiquitinated status of MCK2.  
In conclusion, we have revealed a novel mechanism by which a herpesvirus DUB 
controls the host response to infection and appropriates that response for successful 
infection. While the function of the viral chemokine MCK2 in eliciting and coopting host 
inflammatory responses has been previously described [143-145, 157, 158], we show that 
there is DUB-dependent control of MCK2 expression during infection. Thus, a unique 
interplay between M48 DUB activity and MCK2 function orchestrates a critical step in 
CMV pathogenesis, representing a potential target for therapeutic intervention. 
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Figure 3.13: Proposed model for M48-dependent regulation of MCK2. 
 
If M48 is expressed in the presence of MCK2, its degradation is blocked. Interestingly, a 
WT M48 DUB selectively promotes the degradation of MCK2, leading to its tamed 
expression and a decrease in inflammation. In the presence of the mutant DUB, MCK2 
degradation is still blocked, but there is no selectivity in the amount allowed to be 
degraded, leading to an increase in MCK2 levels, ultimately resulting in increased 






Chapter 4: Conclusions and Future Directions 
4.1 CONTINUED RESEARCH AND DEVELOPMENT ON PATHOGEN 
ELECTROCHEMICAL BIOSENSORS 
4.1.1 Summary of dissertation research 
We recently reported two significant advancements in the field of collision 
electrochemistry. We demonstrated that MCMV could be specifically detected in solution 
by tagging the virus with antibody and binding to polystyrene beads (PSBs), and then 
observing the formation of aggregates [123]. Building off this work, we then focused on 
the development of a positive detection method for MCMV utilizing an enzymatically 
enhanced collision technique to detect virus in the urine of infected mice [43]. Overall, 
these studies have demonstrated the potential use of collision electrochemistry to detect 
pathogens in complex solutions, and offer an easy-to-use and rapid diagnostic technique 
for CMV infection. 
4.1.2 Future of pathogen electrochemical sensors utilizing collision 
electrochemistry 
 
While the enzymatic detection of MCMV represents an impressive step forward, 
the technique does suffer from several foreseeable problems. First, we rely on an 
antibody for viral detection. It is not unreasonable that antibody epitopes may vary, 
which decreases the efficacy of this method. One way in which this problem could be 
solved is by using multiple antibodies, which effectively would increase the possibility of 
positive detection. Assuming detection using antibodies causes few problems, there is 
still an issue regarding the small signal to noise ratio currently inherent to our system. 
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Although our present signal to noise ratio of approximately 15:1 allows the detection of 
distinct events by amperometry, a greater signal to noise ratio would be ideal. To achieve 
this, one could take advantage of the electrochemical amplification properties of 
nanoparticles, such as platinum. These nanoparticles could be labeled with an MCMV- or 
HCMV-specific antibody, similar to the manner in which Spain and colleagues 
electrochemically detected prostate specific antigen [167]. Subsequent collisions with an 
electrode would then produce a robust current response greater (S:N on the order of 
100:1) than that of the background.  
Additional method optimization also includes the mode of mass transfer of 
particles to the electrode. Currently, our method relies on the diffusion of particles to the 
electrode. Because detection dependent on diffusion is directly related to the 
concentration of the particle, samples that are relatively dilute will be difficult to reliably 
detect the presence of viral particles. In this case, it would be necessary to implement 
some sort of ultramicroelectrode (UME) array, thus increasing the chances of a collision 
[168]. Directing the mass transfer of particles by utilizing fluidics device over an 
electrode array would significantly increase the chances of a positive detection event 
[169]. Lastly, while our method could be used for point-of-care diagnostics and continued 
monitoring, if a new patient tests positive for HCMV using this technique, additional 
confirmation in the way of cell culture or PCR-based assays would still be necessary in 
order to confirm the diagnosis before moving forward with treatment.  
Overcoming these hurdles will allow for the rapid development of similar 
detection schemes for any number of different pathogens, including viral, bacterial, 
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fungal and parasitic infections. Recent work from Sepunaru and co-workers showed that 
electrochemically amplified detection of influenza could be achieved by incubating the 
virus with silver nanoparticles and observing the collisions of influenza / Ag-
nanoparticles with an electrode [101]. While significant signal was observed upon 
influenza particle collision at an electrode, this method would not work on a more 
complex sample not entirely comprised of influenza virus as the silver nanoparticles 
would likely non-specifically stick to any particle in solution. Therefore, while significant 
strides have been made in using electrochemistry to detect pathogens, continued research 
and development is necessary for implementation of these collision methods in the clinic.  
4.2 IDENTIFYING AND VERIFYING NOVEL TARGETS FOR ANTI-VIRAL 
CYTOMEGALOVIRUS TREATMENT 
4.2.1 The cytomegalovirus deubiquitinating enzyme as a viable therapeutic target 
Unique enzymatic contributions to HCMV infection are likely to be important to 
viral replication. As such, a major area of research has been to target these enzymes 
through the use of small molecule inhibitors. In chapter 3, I described our recent work 
characterizing the important role of the uniquely structured and conserved MCMV DUB 
in mediating infection dynamics in vivo. Because this DUB is structurally distinct from 
its cellular counterparts, it is possible that with additional research, this DUB could serve 
as another potential target for pharmacological intervention. Interestingly, this idea is not 
new as small molecule inhibitors of cellular DUBs are of significant interest due to the 
tumorigenic potential of some cellular DUBs [170]. As such, currently developed 
inhibitors may serve as solid platforms for anti-CMV DUB drug discovery.  
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Though herpesvirus DUBs share some structural similarities to the papain 
superfamily of proteases, their interactions with ubiquitin are unique [71]. The M48 DUB 
is structurally distinct and seems to derive its specificity for ubiquitin in a beta-hairpin 
region that is critical for its interaction with the ubiquitin hydrophobic patch (M48 a.a. 
108-115). Though the catalytic triad (C23, H158, and D156) responsible for the cleavage 
of ubiquitin is not unique to the herpesvirus DUBs, targeted inhibition of the DUB’s 
ability to act on ubiquitin may be possible by targeting the beta-hairpin. Excitingly, 
predicted structural analyses using the Phyre2 modeling software [171] suggest 
significant structural conservation between M48 and the HCMV DUB, UL48. They even 
seem to share homology in the beta-hairpin. Several of the same residues mediating the 
interaction with the hydrophobic ubiquitin patch appear to be conserved (M48  L110, 
Y113, and C115; UL48  L114, Y117, and C119) (Figure 4.1). To determine the 
contributions of the hairpin to MCMV infection, genetic studies mutagenizing these key 
residues should be conducted. Assuming they contribute to pathogenesis in some 
capacity, the conserved beta-hairpin, along with other distinct structural components [71] 




Figure 4.1: UL48 (amino acids 1-300) modeled and mapped to M48. 
 
Amino acids 1-300 of UL48 (Towne strain) were submitted on the protein fold 
recognition engine, Phyre2. The resulting .pdb file was opened in Jmol and the conserved 
residues located in the beta-hairpin were mapped (L114 blue, Y117red, 





4.2.2 Cytomegalovirus deubiquitinating enzyme mutants as vaccine vectors 
In addition to the development of anti-HCMV therapeutics, the use of HCMV as a 
vaccine vector has been heavily researched due to its ability to successfully activate both 
the innate and adaptive arms of the immune response [128]. In fact, recent work has 
utilized rhesus CMV (RCMV) as a vaccine vector in which simian immunodeficiency 
virus (SIV) antigens have been genetically inserted and subsequently expressed. The 
substantial immune response elicited by RCMV also causes an immune response against 
the SIV antigens. Subsequent challenges with SIV were unproductive in 50% of the 
monkeys as a result of the immunization provided [172 , 173]. Due to the increased 
inflammatory response and type I interferon response elicited by a mutant DUB MCMV 
[87, 174], it may be that a mutant DUB HCMV elicits both a more robust and potent 
immune response. While it remains to be determined if the HCMV DUB functions in the 
same manner as the MCMV DUB, co-transfection of the HCMV DUB UL48 (WT or 
mutant) with MCK2 resulted in increased MCK2 secretion in the presence of the mutant 
DUB similar to the result seen in Figure 3.4b (Figure 4.2). These results suggest at least 
some conserved functionality between the two proteins. Future efforts will seek to 
determine host immune responses to mutant DUB MCMV and other non-human primate 
CMVs to determine what these precise immunological changes are. Results from these 
studies will not only yield important insight into CMV-mediated immune responses, but 




Figure 4.2: Mutant DUB UL48 facilitates an increased MCK2 secretion. 
 
NIH3T3 cells were co-transfected with UL48 (WT or mutant DUB) and MCK2. MCK2 
secretion was assessed as previously described (Figure 3.4b). Expression of the indicated 








4.3 OVERALL CONCLUSIONS 
 
In conclusion, we have demonstrated the feasibility of a rapid, facile point of care 
diagnostic technique that, if implemented in the clinic in the future, would allow for early 
detection and treatment against HCMV infection. Additionally, we have characterized 
and identified a major role for a highly conserved MCMV deubiquitinating enzyme. As 
this enzyme represents a uniquely structured viral protein, it may serve as an additional 
target against which anti-CMV drugs can and will be developed. These two studies 
fundamentally represent substantial steps forward in CMV diagnosis and identification of 
possible targets for CMV treatment. Though significant knowledge has been gained as a 
result of these studies, continued improvements to CMV diagnosis and identification of 
unique viral contributions to infection must be made in order that CMV-caused diseases 













Chapter 5: Materials and Methods 
5.1 CHAPTER 2 MATERIALS AND METHODS [123] 
5.1.1 Chemicals  
Water used in each experiment was Milli-Q water. Ferrocyanide was purchased 
from Fisher Scientific and used without further purification. Ferrocenedimethanol was 
purchased and used without further purification. Goat anti-mouse IgG (Fc) coated 
polystyrene particles (0.7–0.9 μm) were purchased from Spherotech and stored at 4 
degrees centigrade. Before using the solution, the bottle was vortexed for 1 min and 
sonicated using a Q500 ultrasonic processor (Qsonica). Potassium nitrate (KNO3, 99.8%) 
was purchased from Fisher Scientific. All chemicals were used as received. 
5.1.2 Electrochemistry 
Electrochemical experiments were performed using a CHI model 900B 
potentiostat (CH Instruments). The Pt UME was prepared following the general 
procedure developed in our laboratory [175].The three-electrode cell was placed in a 
faraday cage and grounded to a pipe. An Ag/AgCl (1 M KCl) wire was used (BASi) as 
the reference electrode, and a Pt wire was used as the auxiliary electrode. Generally, 
experiments were performed in a 20-mL glass vial with a homemade vial cap to position 
the electrodes in the solution. 
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5.1.3 Optical analysis 
DLS was obtained using a Zetasizer Nano ZS (Malvern). NTA was also used to 
analyze the virus particles by Nanosight. Here, scattering light from a laser illuminates 
particles. A movie of these particles is taken, and the software traces the movement of the 
nanoparticle. This movement allows the software to calculate a diffusion coefficient and 
use the Stokes–Einstein relation to back-calculate the hydrodynamic radius. SEM images 
were obtained using an FEI Quanta 650 ESEM. The optical images were taken using a 
Nikon Eclipse TE300 inverted microscope with a 100× objective lens and a camera 
attachment to the eyepiece. 
5.1.4 Virus propagation and purification 
Bacterial artificial chromosome derived wild-type MCMV (strain K181-Perth) 
and MHV68 WUMS [obtained from American Type Culture Collection (ATCC) 
#VR1465] were generated on NIH 3T3 fibroblasts (ATCC, #CRL-1658) as previously 
described [176, 177]. Viral stocks were propagated, clarified, and concentrated as 
previously described [145]. Sorbitol density gradient purification was performed as 
previously described to purify the virus [178]. Briefly, concentrated virus was 
resuspended in complete DMEM supplemented with 10% bovine calf serum, layered 
over 20% sucrose cushion, and centrifuged 60 min at 32,800 × g. Pelleted virus was 
resuspended in Tris-buffered saline (0.05 M Tris, 0.10 M NaCl, pH 7.4), placed onto a 
20–70% continuous linear sorbitol gradient, and subjected to ultracentrifugation at 70,000 
× g for 60 min at 16 °C. Virion band was visualized using light scatter from an overhead 
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light source, and collected by needle aspiration. Samples were subjected to a second 
round of ultracentrifugation to remove additional contaminants. 
5.1.5 Antibody and bead adsorption 
Mouse monoclonal anti-gB neutralizing antibody (Clone MAb97.3) was provided 
by Michael Mach, University of Erlangen, Germany. Preparation of the MCMV-A 
samples was as follows: Infectivity experiments were completed to gauge how much 
antibody would render the virus noninfectious under the assumption that a noninfectious 
virus is saturated with antibody. A 1:1 (vol/vol) virus to antibody solution was mixed 
together and allowed to incubate at 37 degrees centigrade for 1 hour. A new sample was 
made for each experiment, and experiments were performed in triplicate. For the 
MHV68, a similar method of preparation was performed as for MCMV. For the PSB 
measurements, a similar procedure was followed. Here, the PSBs were added to the virus 
and antibody mixture. The PSB, MCMV, MAb 97.3 mixture was incubated at room 
temperature for another hour. 
 
5.2 CHAPTER 2 MATERIALS AND METHODS [43] 
5.2.1 Chemicals  
Ferrocene methanol (98%) was purchased from Sigma-Aldrich. Solutions of 
ferrocene methanol were prepared by sonicating the solution for at least 20 min to 
dissolve ferrocene. This solution as then passed through a 100-nm pore filter. Glucose 
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was purchased from Fisher Scientific and used without further purification. In each case, 
nanopure water was used for the experiments. 
5.2.2 Electrochemistry 
Electrochemical experiments were performed using a CHI model 900B 
potentiostat (CH Instruments). The three-electrode cell was placed in a faraday cage and 
grounded to a pipe. An Ag/AgCl (1 M KCl) wire was used (BASi) as the reference 
electrode, and a Pt wire was used as the auxiliary electrode. 
 
5.2.3 Electrode fabrication 
The Pt UME was prepared following the general procedure developed in our 
laboratory [175]. Electrodes were fabricated using a laser puller (Sutter Instruments) 
followed by a soft mechanical polishing until the electrode was 0.5–3 μm in radius. 
Briefly, a 25-μm-diameter Pt wire was placed in a glass capillary pulled to nanometer 
dimensions after a laser pulse locally heated and melted the glass and Pt. This electrode 
was then mechanically polished to the necessary size. 
5.2.4 Glucose oxidase conjugation 
GOx was covalently attached to purified anti-gB neutralizing antibody. Briefly, 
MCMV gB antibody, Mab97.3 kindly provided by Michael Mach, University of 
Erlangen, Erlangen, Germany, was purified from supernatant by way of affinity 
purification using agarose beads conjugated to protein A/G (Santa Cruz). Purified 
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antibody was eluted from the protein A/G beads with 0.15% TFA. The elution solvent 
was removed via vacuum concentration (Speed Vac; Thermo Fisher) and resuspended in 
1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4). 
Antibody concentration was determined via Bradford assay. The conjugation reaction 
was performed using a Glucose Oxidase Conjugation Kit (ab102887; Abcam) as per the 
manufacturer’s instructions. The conjugate was incubated in the electrochemical samples 
for 30 min at 4 °C. 
5.2.5 Virus purification 
Both MCMV and MHV68 virions were prepared as previously described [123]. 
Briefly, concentrated virus was resuspended in complete DMEM supplemented with 10% 
(vol/vol) bovine calf serum, layered over 20% (wt/vol) sucrose cushion, and centrifuged 
60 min at 32,800 × g. Pelleted virus was resuspended in Tris-buffered saline (0.05 M Tris 
and 0.10 M NaCl, pH 7.4), placed onto a 20–70% (wt/vol) continuous linear sorbitol 
gradient, and subjected to ultracentrifugation at 70,000 × g for 60 min at 16 °C. The 
virion band was visualized using light scatter from an overhead light source and collected 
by needle aspiration. Samples were subjected to a second round of ultracentrifugation to 
remove additional contaminants. 
5.2.6 Animal infections 
C57BL/6J mice were infected with 10
6
 pfu of WT MCMV via i.p. route of 
infection. Urine collection was performed at 3, 5, 7, 10, and 14 d post-infection. Control 
mice were infected with media only. Animals were maintained by the Animal Resources 
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Center (ARC) at the University of Texas at Austin in accordance with Institutional 
guidelines, and all procedures were approved by the University of Texas at Austin 
Institutional Animal Care and Use Committee. 
5.3 CHAPTER 3 MATERIALS AND METHODS  
5.3.1 Plasmids and transfections 
Transfections were performed with GenJet in vitrotransfection reagent (Ver. II; 
SignaGen Laboratories) per the manufacturer’s instructions. Carboxy-terminal 3XFLAG 
epitope-tagged MCK2 was generated by PCR amplification of nucleotides 188352 to 
187431 from pARK25 (Redwood et al, 2005), a bacterial artificial chromosome (BAC) 
containing the K181 (Perth) strain MCMV (GenBank accession number AM886412.1). 
Amplicons were cloned into the EcoRI and XbaIsites of p3XFLAG–CMV-14 (Sigma-
Aldrich). An untagged MCK2 expression construct was similarly generated by PCR and 
the resulting amplicon cloned into the KpnI and BamHI sites of pcDNA3.1(+). Carboxy-
terminal EGFP-tagged M48 and M48
C23S
 were generated by PCR amplification of 
nucleotides 67043 to 67897 (amino acids [a.a.] 1 to 285) or 67043 to 73483 (full length) 
of either WT BAC or M48
C23S
 BAC, respectively. Both the full-length and M48
(1–
285)
 constructs were cloned into the HindIII and KpnI sites of pEGFP-N1 (Clontech). 
Plasmids pQE9-His-p97(wt) and pQE9-p97(QQ) (Addgene plasmids 14666 and 14667, 
respectively) were a gift from Graham Warren (Meyer et al, 2000; Ye et al, 2001). 
Insertions were amplified by PCR with an N-terminal 6-His tag and cloned into 




NIH3T3 murine fibroblasts (ATCC CRL-1658) were propagated in Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma-Aldrich) containing 10% heat-inactivated 
bovine calf serum (BCS; Life Technologies, Inc.) and 1% penicillin-streptomycin-
glutamine (Life Technologies, Inc.). RAW264.7 murine macrophages (ATCC TIB-71) 
and SVEC4-10 endothelial cells (ATCC CRL-2181) were propagated in DMEM (Sigma) 
containing 10% heat-inactivated fetal calf serum (Life Technologies, Inc.) and 1% 
penicillin-streptomycin-glutamine (Life Technologies, Inc.). 
5.3.3 BAC mutagenesis and recombinant viruses 
pSIM6 plasmid, containing genes necessary for λ-red recombination, was 
introduced into bacteria containing pARK25 (Redwood et al, 2005). Recombineering for 
K181-BAC mutagenesis was performed as previously described (Upton et al, 2010). 
Genome integrity was confirmed by restriction fragment length polymorphism analysis, 
and mutagenesis was verified by PCR, restriction digest, and sequencing of the targeted 
region of M48 and m131. BAC-derived parental and recombinant viruses were generated 
and purified as previously described (Redwood et al, 2005). Viruses were propagated, 
clarified, and concentrated, and the titers were determined by plaque assay on NIH3T3 
cells as previously described (Saederup et al, 1999). Growth curve experiments were 
performed in 12-well plates at the indicated multiplicity of infection (MOI) in 0.4 ml for 
2 h at 37°C. After adsorption, cells infected at an MOI of 5.0 were washed twice with 
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phosphate-buffered saline (PBS) and refed. Cells infected at an MOI of 0.05 in a volume 
of 0.4 ml were given additional complete DMEM to reach a volume of 1 ml. Cells and 
supernatants were harvested at the indicated times, and titers were determined via plaque 
assay on NIH3T3 fibroblasts. 
5.3.4 Immunoprecipitation and immunoblotting 
Culture supernatants collected from MCK2/M48-cotransfected cells were cleared 
of cell debris by spinning at 5,000 × g for 15 min. IPs were performed by adding anti-
FLAG M2-agarose slurry (Sigma-Aldrich) followed by incubation on an orbital rotator 
overnight at 4°C. Cell lysates and IP samples were separated by SDS-PAGE on 10% 
acrylamide gels or Mini-Protean TGX precase 4% to 20% gradient gels (Bio-Rad). 
Proteins were transferred to nitrocellulose membranes (GE Healthcare Life Sciences) and 
subjected to immunoblot analysis with indicated antibodies. The following antibodies 
were used in immunoblot analyses: mouse anti-MCK2 (clone 11D7; gift from Peggy 
MacDonald, the Rockefeller University), mouse anti-m123/IE1 (Chroma101; Center for 
proteomics, University of Rijeka), mouse anti-m112-113/E1 (Chroma103; Center for 
proteomics, University of Rijeka), rabbit anti-M86 (MCP) (gift from Laura Hanson, 
Texas Woman’s University), mouse anti-β-actin (clone AC-74; Sigma-Aldrich), mouse 
anti-GFP (clone 4B10; Cell Signaling Technology, Inc.), mouse anti-FLAG M2-
peroxidase (clone M2; Sigma-Aldrich), mouse anti-ubiquitin (clone P4D1; Santa Cruz), 
mouse anti-6-His (THE His Tag antibody; GenScript), anti-mouse IgG-horseradish 
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peroxidase (IgG-HRP) (Vector Laboratories), and anti-rabbit IgG-HRP (Vector 
Laboratories). 
5.3.5 PNGase F treatment 
PNGase F treatments were performed according to the protocol of the 
manufacturer (NEB) for denaturing conditions. Briefly, whole-cell lysate in NP-40 lysis 
buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl—pH 8.0) was diluted with 
denaturing buffer and boiled for 10 min. Reaction buffer (10×; diluted to 1×), NP-40 
(1%), and PNGase F were added, and the reaction mixture was incubated at 37°C for 1 h. 
Samples were then analyzed by immunoblotting. 
 
5.3.6 Virus purification 
Virions were purified over a 20% to 70% linear sorbitol gradient as described 
previously [123]. Briefly, extracellular virions were collected from infected cell 
supernatants via centrifugation at 20,000 × g for 1.5 h at 4°C. Virion pellets were 
collected and then passed over a 20% sucrose cushion for 1 h at 16°C and 32,800 × g. 
The cushion-purified virus was resuspended in 1 ml of TN buffer (50 mM Tris-HCl and 
100 mM NaCl, pH 7.4), briefly sonicated, and placed on the top of the linear gradient. 
Gradients were centrifuged at 76,000 × g in an SW41 swinging-bucket rotor for 1 h at 
16°C. Virion-containing bands were collected by aspiration, diluted in buffer, and 
pelleted by centrifugation at 100,000 × g for 3 h at 16°C. 
 117 
5.3.7 Sample preparation for LC-MS/MS analysis 
Pelleted virions were resuspended in TN buffer, and 2,2,2-trifluoroethanol (TFE) 
(Sigma-Aldrich) was added to reach a final concentration of 50% TFE. Proteins were 
reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) for 45 min at 55°C followed 
by alkylation with 15 mM chloroacetamide at room temperature, in the dark, for 30 min. 
Excess chloroacetamide was quenched with 20 mM dithiothreitol (DTT), and samples 
were diluted 10-fold to reach a final concentration of 5% TFE–digestion buffer (50 mM 
Tris [pH 8.0], 2 mM CaCl2). Trypsin was added to reach a final concentration of 1:50 
(enzyme/protein), and the digests were incubated at 37°C for 5 h. The digests were 
quenched by addition of formic acid to reach a final concentration of 1%. Tryptic digests 
were vacuum centrifuged to reduce the volume to approximately 100 to 150 μl. Buffer 
exchange was performed with Hypersep SpinTip C18 SPE tips (Thermo Scientific) 
according to the manufacturer instructions. Briefly, resin was washed 3 times with a 60% 
acetonitrile–0.1% formic acid solution and then equilibrated with buffer A (0.1% formic 
acid–water). Peptides were passed over the resin, after which bound peptides were 
washed 3 times with buffer A and eluted with the 60% acetonitrile–0.1% formic acid 
solution. Eluted peptides were briefly dried via vacuum centrifugation and resuspended in 
5% acetonitrile–0.1% formic acid. Peptides were stored at −80°C until liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis. 
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5.3.8  LC-MS/MS analysis 
Samples were analyzed by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), with a minimum of three replicate injections analyzed per sample. 
Peptides were separated by reverse-phase chromatography on a Dionex Ultimate 3000 
nanoRSLC system (Thermo Scientific) with an Acclaim PepMap 100 RSLC C18 column 
(Thermo Scientific) (15 cm), using an acetonitrile gradient (3% to 38% over 215 min). 
Eluting peptides were directly analyzed by nano-electrospray ionization-tandem mass 
spectrometry on an Orbitrap Velos Pro mass spectrometer (Thermo Scientific). Full 
spectra (MS1) were collected at a resolution of 100,000. Fragmentation spectra (MS2) 
were collected in a data-dependent manner, with ions required to carry a charge of +2 or 
greater for MS2 selection, and up to 20 MS2 scans were collected per round. Dynamic 
exclusion was employed, whereby ions selected twice within 30 s were excluded from 
selection for 45 s. 
5.3.9  MS data analysis and protein quantitation 
A searchable protein sequence database was constructed from MCMV (strain 
K181) and mouse reference proteomes (UniProt) and common contaminants (from the 
MaxQuant website; http://maxquant.org/downloads.htm). MS spectra were searched 
against this database using SEQUEST (Proteome Discoverer 1.4; Thermo Scientific). The 
database was curated to include the m129/m131 spliced product. Fully tryptic peptides 
with up to 2 missed cleavages were considered. Mass tolerance filters of 10 ppm (MS1) 
and 0.5 Da (MS2) were applied. Modifications of cysteine carbamidomethylation (static; 
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+57.0215 Da) and methionine oxidation (dynamic; +15.9949 Da) were allowed, with no 
more than three modifications allowed per peptide-spectrum match (PSM). False-
discovery rates (FDR) for PSMs were determined by decoy database error modeling 
using Percolator (Proteome Discoverer 1.4; Thermo Scientific), and a set of high-
confidence PSMs were selected for further analysis at an FDR of <1%. Extracted-ion 
chromatograms (XICs) of MCMV-derived peptides were manually inspected using the 
Skyline software package [179] to identify target ions exhibiting minimal interference 
and limited variability across replicate injections. The top three highest-quality target ions 
were selected for each protein of interest and XIC peak areas exported for calculation of 
relative abundances. XIC peak areas were first normalized to the major capsid protein 
M86 (MCP) by dividing XIC peak areas by the mean of the values determined for the 
three M86 (MCP) target ions. Normalized values were averaged across replicate 





 samples. Finally, mean averages and standard deviations of target ion ratios were 
calculated for each protein. 
5.3.10 Animal experiments 
C57BL/6J mice were obtained from the Jackson Laboratory. Animals were bred 
and maintained at the Animal Resources Center (ARC) at the University of Texas at 
Austin in accordance with Institutional guidelines, and all procedures were approved by 
the University of Texas at Austin Institutional Animal Care and Use Committee. Six- to 
10-week-old male and female animals were infected with 10
6
 PFU by inoculation into a 
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rear footpad or by intraperitoneal (i.p.) injection, as previously described [180]. Upon 
sacrifice, organs were placed into 1 ml of complete DMEM, subjected to a single 
freeze/thaw cycle (−80°C), and disrupted by sonication. Organ homogenates were 
serially diluted, and the titers were determined by plaque assay on NIH3T3 fibroblasts. 
Footpad measurements were taken at the indicated time points with a digital caliper, as 
previously described [144]. Unless otherwise indicated, each time point represents n of 
≥5. 
5.3.11 Fluorescence microscopy 
NIH3T3 cells were grown to the desired confluency in a 6-well plate before being 
transfected with 1 μg of either pEGFP-N1 empty vector (EV), pEGFPN-1-M48, or 
pEGFPN-1-M48
C23S
. 24 hours post transfections, cells were washed twice with 1X 
phosphate buffered saline (PBS) before being fixed in 4% paraformaldehyde for 20 
minutes at room temperature. After 3 washes in 1X PBS, cells were permeabilized with 
0.5% Triton X-100 (in 1X PBS) on ice for 10 minutes. After 3 more washes with 1X 
PBS, cells were incubated at room temperature with Hoechst stain for 10 minutes. After 1 




5.4 CHAPTER 4 MATERIALS AND METHODS  
5.3.1 Plasmids and transfections 
Transfections were performed with GenJet in vitrotransfection reagent (Ver. II; 
SignaGen Laboratories) per the manufacturer’s instructions. Carboxy-terminal 3XFLAG 
epitope-tagged MCK2 was generated by PCR amplification of nucleotides 188352 to 
187431 from pARK25 [176], a bacterial artificial chromosome (BAC) containing the 
K181 (Perth) strain MCMV (GenBank accession number AM886412.1). Amplicons were 
cloned into the EcoRI and XbaIsites of p3XFLAG–CMV-14 (Sigma-Aldrich). Wildtype 
UL48 (myc6-UL48) as well as mutant DUB UL48 (myc6-UL48
C24S
) were kindly 
provided by Jin-Hyun Ahn (Department of Molecular Cell Biology, Samsung Biomedical 
Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of 
Korea) [97].   
5.3.4 Phyre2 analysis 
Amino acids 1-300 of HCMV UL48 (Towne strain; GenBank FJ616285.1) were 
analyzed using the online protein fold recognition server, Phyre2 [171]. The obtained 
results indicated that 80% of the UL48 sequence (1-300) matched with 100% confidence 
to the previously crystalized M48 DUB [71]. Conserved residues in the beta-hairpin of 
UL48 were mapped using Jmol [181]. 
5.3.5 Immunoprecipitation and immunoblotting 
Culture supernatants collected from MCK2/M48-cotransfected cells were cleared 
of cell debris by spinning at 5,000 × g for 15 min. IPs were performed by adding anti-
FLAG M2-agarose slurry (Sigma-Aldrich) followed by incubation on an orbital rotator 
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overnight at 4°C. Cell lysates and IP samples were separated by SDS-PAGE on 10% 
acrylamide gels or Mini-Protean TGX precast 4% to 20% gradient gels (Bio-Rad). 
Proteins were transferred to nitrocellulose membranes (GE Healthcare Life Sciences) and 
subjected to immunoblot analysis with indicated antibodies. The following antibodies 
were used in immunoblot analyses: mouse anti-FLAG M2-peroxidase (clone M2; Sigma-
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